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When a pathogen invades the body, an acute inflammatory response is activated to eliminate
the intruder. In some patients, runaway activation of the immune system may lead to collat-
eral tissue damage and, in the extreme, organ failure and death. Experimental studies have
found an association between severe infections and depletion in levels of adenosine triphos-
phate (ATP), increase in nitric oxide production, and accumulation of lactate, suggesting
that tissue energetics is compromised.
We present a computational model consisting of ordinary differential equations to explore
the dynamics of the acute inflammatory response against infections caused when a pathogen
makes its way into a host. This model incorporates energy production along with the energy
requirements that arise when fighting such an infection. In particular, we investigate the
role of energetics during infection and explore the relation between overproduction of nitric
oxide (NO), lactate, altered adenosine triphosphate (ATP) levels, and sepsis.
Finally, a data-driven approach is used to extend our model as an effort to better under-
stand the role of energy in sepsis. This extended model is calibrated by fitting animal data
from a study done in thirty-two baboons that were induced into sepsis after infusing E. coli
intravenously. Using Bayesian analysis, we quantify uncertainty in model parameters and
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When pathogens enter the body, a complex chain of reactions occurs in which the immune
system activates and attempts to eliminate the intruders and prevent persistent infection.
For a short period of time, invading pathogens can reproduce rapidly. However, encounters
with pathogens activate immune cells, such as macrophages and neutrophils, which release
signaling molecules such as cytokines and eliminate pathogens through means such as phago-
cytosis and recruitment of additional immune cells. Under normal circumstances, as long
as the initial insult is sufficiently limited, the immune response will satisfactorily eliminate
the pathogen and the host will become healthy again. In some cases, however, the initial
response may escalate into an overwhelming systemic inflammation. Such overreaction of
the immune system can lead to tissue damage, organ failure, and possibly death. This state
of uncontrolled inflammation is known as sepsis. Every year severe sepsis affects more than
1.7 million people in the U.S. alone and over 30 million people worldwide [1].
Several studies have found associations between overproduction of nitric oxide (NO), mi-
tochondrial dysfunction, and sepsis [12], [13], [14]; moreover, it has been proposed that septic
organ failure is caused by depression of mitochondrial function, [18]. Because mitochondria
are organelles responsible for the generation of most of the energy in a cell, mitochondrial
dysfunction directly affects the production of ATP, which could contribute to this associa-
tion. For instance, in a study performed on skeletal muscle of 28 patients with sepsis, [12]
observed a relation between overproduction of NO, mitochondrial dysfunction and lowered
adenosine triphosphate (ATP) levels. They reported a decrease in mitochondrial complex I
activity, the magnitude of which was associated with the degree of NO production in skele-
tal muscles of patients admitted to intensive care with septic shock. In a subsequent study,
similar results were found in muscle and liver in a long-term rodent model of fecal peritonitis
[13]. Furthermore, [14] found that adding NO to isolated rat brain mitochondria inhibits
ATP synthesis. Since ATP provides energy for physiological processes including activation
of immune cells, production and release of signaling molecules, protein synthesis, and tissue
repair [17], [16], lowered ATP levels are likely to compromise aspects of the inflammatory
1
response; yet, since this response involves a complex balance of pro- and anti-inflammatory
effects, the impact of these ATP-related alterations is not straightforward to predict.
Computational modeling provides an approach to deriving predictions about complex
biological systems that can effectively complement experimental work and allow the explo-
ration of manipulations that may not be experimentally feasible. In particular, a variety
of previous works have drawn insights from reduced computational models of the inflam-
matory response. Often such models lump cytokine actions into a small number of classes
exhibiting coarsely similar properties or simply combine together all pro-inflammatory com-
ponents of the response, but they nonetheless can provide useful information. For instance,
[47] proposed a simplified model for acute inflammation that includes pathogens, early pro-
inflammatory effectors such as macrophages and neutrophils, and late pro-inflammatory
feedback; despite its simplicity, the model yielded predictions about how changes in biolog-
ically interpretable parameters influenced inflammatory outcomes and was used to suggest
therapeutic strategies. Soon afterwards, another reduced model was developed to describe
the dynamics of the acute inflammatory response including pathogens, tissue damage and
activated neutrophils along with an anti-inflammatory mediator, which was used to study
how the dynamics of anti-inflammatory feedback contribute to patient outcomes, [61]. A
related model was also used to suggest possible explanations for tolerance effects arising
with repeated endotoxin exposure, [26]. A somewhat more detailed model for the acute
inflammatory response was shown to fit data from mice exposed to various inflammation-
inducing insults and was used to predict mortality outcomes following endotoxin injection
[19], while another work used parameter optimization based on fits to data to demonstrate
both that different balances of inflammatory processes could yield similar cytokine dynamics
yet with different mortality expectancies, [24]. Such models have also been used to study
control strategies for inflammation, [25], as well as to explore the impact of blood filtration
on inflammation, [57].
Unlike these earlier models, [23] derived several compartmental models describing the
interaction between energy resources, a general pool of immune cells, and pathogens. These
models were employed to study the scenario when the immune agents and pathogens have
separate resources and the case when both depend on the same source. However, these models
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do not incorporate signaling components of the immune response, such as pro- and anti-
inflammatory cytokines, and their level of abstraction poses an obstacle for model comparison
with human and animal data.
In contrast to these works, other modeling frameworks offer alternatives that take into
account spatiotemporal dynamics. For example, partial differential equations have been
used to study the immune response to antigen including spatial effects such as immune
cell recruitment and granuloma formation, [73]. Similarly, agent-based models that treat
pathogens as well as immune-related molecules and cells as discrete agents that move around
in a spatial domain have been used in a variety of works (e.g., [27] and the references therein).
In these models, biological mechanisms can be encoded in rules used to perform discrete
temporal updates of system states. We instead work with continuous ordinary differential
equation models because we wish to apply dynamical systems methods such as bifurcation
analysis and because our study is motivated by data sets that lack spatial information.
This thesis can be subdivided in two large stages: a forward problem and an inverse or
backward problem. The forward problem is presented in Chapter 2, which is the foundation of
our work, as we present an initial mathematical model that encloses the dynamics of the acute
inflammatory response including the energy requirements to fight an infection. Numerical
analysis of the model help to understand important model features. We use this model as
a tool to study the effect of metabolic conditions such as hypoglycemia, hyperglycemia, and
hypoxia.
We continue in Chapter 3, where we extend our initial model presented in Chapter 2
to include new state variables that were observed in an experimental study performed in
baboons who were induced into sepsis by bacterial infusion. Chapter 4 builds in the model
developed in Chapter 3 and it consists of solving the backward problem of parameter estima-
tion given the observed data. We follow a Bayesian approach to construct a distribution of
virtual patients and determine model parameter densities to quantify uncertainty in model
parameters. Next, in Chapter 5 we use our model to revisit the effect of hypoglycemia and
hyperglycemia in a virtual population. We also adapt our model to study the role of an
NOS inhibitor, a drug treatment used in the same baboon study. Further, we use logistic
regression to identify key parameters that can be used to predict patient outcome. Lastly,
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Chapter 6 concludes with final remarks and conclusions.
Some of the main goals that will be addressed in the second stage of this thesis are to
understand what biological factors determine whether a patient will end up being a survivor
or a not survivor. And within the non-survivors, the same question between septic and
aseptic patients. Similarly, we are interested in finding what biological factors determine
whether a patient will survive or not after treatment. We also want to predict from patient
data whether a patient will be a survivor or non-survivor. And to understand effects of
energy-related conditions on patient outcomes.
By the time of thesis submission only the work presented in Chapter 2 has been published,
[59].
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2.0 Mathematical modeling of energy consumption in the acute inflammatory
response
2.1 Introduction
This chapter is based on our published work [59]. Here, we develop a computational model
to study the dynamics of acute inflammation that incorporates a reduced representation
of relevant metabolic pathways and energy resources and demands. We use our model to
investigate the role of energetics during infection and to explore the relation between over-
production of NO, altered ATP levels, and sepsis. Moreover, disorders in energy metabolism
or other alterations in metabolic states, such as hypoglycemia, hyperglycemia and hypoxia,
can trigger organ dysfunction as is characteristic in patients with sepsis [28]. These condi-
tions can be associated with low levels of ATP and with lactate accumulation, and thus we
apply our model to predict their impact on the acute inflammatory response as well.
This chapter is organized as follows. In Section 2.2, we provide a complete and detailed
description of the mathematical model that we have developed. In Section 2.3, we present an
analysis of the model starting with numerical simulations, bifurcation analysis and compu-
tation of basins of attraction of stable states across varying levels of pathogen growth rate.
These results are followed in Section 2.4 by the application of the model to study the altered
metabolic conditions of hypoglycemia, hyperglycemia, and hypoxia in comparison with base-
line states. Finally, in Section 2.4.4 we perform a survival analysis for 300 virtual patients
and compare their outcomes under each of the conditions mentioned above. In Section 2.5,
we conclude with a discussion.
5
2.2 Mathematical model
Here we present a reduced model of immune response to pathogen infection that includes
several pro-inflammatory and anti-inflammatory drivers and that accounts for the energy
consumption associated with the immune response and the effect of energy imbalance on the
system. This model builds on the work of [61] and consists of eight nonlinear ordinary differ-
ential equations that describe the interactions between the immune response to a pathogen
and the associated energy production and demand. As in the Reynolds model, the state
variable P denotes the number of pathogens present, N is the level of active phagocytes and
also represents their pro-inflammatory effects, D is a marker of tissue damage, and CA de-
notes the level of anti-inflammatory mediators. In addition, we introduce new state variables
An, Ab, X, and L as follows: An measures the levels of ATP produced by phagocytes such
as neutrophils and macrophages, Ab corresponds to the levels of ATP generated by all other
cells in the body, and X and L are the levels of NO and lactate in the host, respectively.
With this choice of new variables we seek to study the role of ATP in acute inflammation
including the contributions of NO and the implications for lactate production. The inclusion
of lactate is motivated by the fact that it is commonly measured as a risk factor for sepsis
in the ICU; similarly, levels of ATP and of by-products of NO such as nitrate are available
in animal data. Several terms in the model feature an ATP-dependent factor that scales the
vigor of the process based on the availability of the relevant energy supply, while a collection
of energy flux terms in the ATP equations effect energy consumption.
Our model is based on the interactions shown in Fig. 1. When pathogens enter the
body, a complex chain of reactions occurs, starting with tissue damage and activation of
phagocytes N . These activated effectors induce inflammation followed by a surge of anti-
inflammatory cytokines that balance the recruitment of more phagocytes and down-regulate
the production of harmful substances such as NO (X). Unlike previous work [61], we do
not include a direct reciprocal interaction between N and D; that is, in our model N does
not directly promote D. Instead, both N and D produce X, which in turn promotes D.
These interactions clearly represent a positive feedback loop: NO causes tissue damage while
tissue damage induces more inflammation that enhances NO release. Since every metabolic
6
Figure 1: Interactions between the eight variables appearing in the system of equations (1)-
(8). The system includes pathogens (P ), a marker of tissue damage (D), active phagocytes
(N), anti-inflammatory mediators (CA), nitric oxide (X), and lactate (L), while An and Ab
correspond to the levels of ATP produced by phagocytes and all other cells in the body,
respectively. Arrows and bars indicate up and down regulation, respectively. The effects on
model components influenced by levels of An are indicated by green arrows and bars while
the effects dependent on Ab are denoted in purple.
process requires energy in the form of ATP, the intensities of phagocyte activation, pathogen
elimination, healing of tissue and production of anti-inflammatory mediators in the model
are all modulated by ATP levels. Finally, as a byproduct of anaerobic ATP production,
lactate L is produced.
The ATP energy source for the inflammatory response is produced in the cytosol and mi-
tochondria through the sequential processes of glycolysis and oxidative phosphorylation, the
latter of which requires oxygen (Fig. 2). Although in anaerobic respiration fewer molecules
of ATP are produced, this process is about 100-times faster than oxidative phosphorylation
and therefore is preferred for some immune cells as a quick source of energy, even if oxygen
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is abundant. Moreover, sites of inflammation are often hypoxic environments and although
some oxydative phosphorylation takes place, neutrophils and macrophages depend mostly
on glycolysis for energy production, [9, 58]. Thus, we will introduce separate equations for a
phagocyte ATP level, An, and an ATP level available to other cells in the body, Ab. Indeed,
ATP is produced locally and has a very short half-life, justifying the use of two physically
separated pools of ATP. Within each pool, both glycolysis and oxidative phosphorylation
contribute to ATP production, although to different extents. Oxidative phosphorylation in
both pools is compromised by X due to the known competitive inhibitory effect of NO on
this pathway.
The following system of differential equations incorporates these many biological con-
siderations. Values and meanings for all parameters are given in Table 2; note that the
saturating function g modulates energy-intensive terms based on availability of relevant
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((1− λgb) c(Ab) + (1− λgn) c(An))− µLL (8)
where
f (V ) =
1
1 + V 2
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The first four equations in system (1)-(8) are based on the model given in [61], where
the reader can find a more detailed explanation of the derivation of these equations as well
as a detailed description of the parameters used there. For consistency, we kept the same
variable and parameter nomenclature. In equation (1), the dynamics of P is driven by a
logistic growth term where kpg and P∞ are the growth rate and carrying capacity of P ,
respectively. The second term of this equation describes the elimination of P by nonspecific
immune responses, such as defensins and nonspecific antibodies [61]. We assume that this
process includes two mechanisms: one that is local with negligible energy requirements
and a second where the phagocytes spend energy either traveling to the infected area or
activating. The third and last term of the P equation describes the removal of pathogens
by activated neutrophils N through phagocytosis, the efficacy of which depends on An and
is down-regulated by the anti-inflammatory mediators CA.
In a positive feedback cycle, pro-inflammatory cytokines activate phagocytes, while ac-
tivated phagocytes in turn release these cytokines. As in [61], since our model includes a
single combined pro-inflammatory variable N , we collapse this cycle into a positive feedback
of N on itself, which appears in the first term of equation (2). This term also includes the
recruitment of pro-inflammatory effects by tissue damage and by processes triggered by the
presence of pathogen, all modulated by An and CA. Equation (2) also includes a depletion
term that encompasses an intrinsic decay rate µn as well as an energy-dependent collateral
damage effect from phagocytosis.
The production of tissue damage D is controlled in equation (3) by the Hill function
h(X +P ), based on the assumption that both NO and pathogens promote D; indeed, NO is
also associated with microvascular damage, organ dysfunction and induction of programmed
cell death, or apoptosis. This term includes the same exponent used previously [61], which
9
Figure 2: Schematic diagram of cellular respiration. One molecule of glucose is metabolized
into two molecules of pyruvate. In the presence of oxygen, pyruvate enters mitochondria to
be oxidized into acetyl-CoA by a process called pyruvate decarboxylation. Acetyl-CoA is
then metabolized in the tricarboxylic acid cycle (TCA) or Krebs cycle. Here, acetyl-CoA
undergoes a cycle of reactions where some ATP, as well as ETC substrates (such as NADH)
are produced. These substrates, by virtue of electron exchange in the ETC, generate an
electrochemical gradient at the internal mitochondrial inner membrane that is associated to
the production of more ATP as protons move along this gradient. About 30 molecules of ATP
are produced in this process. In contrast, in the absence of oxygen (anaerobic respiration
or glycolysis respiration), the molecules of pyruvate are synthesized into two molecules of
lactate in a process called fermentation. In this metabolic pathway only two molecules of
ATP are produced. Anaerobic respiration, also called anaerobic glycolysis, is about 100-
times faster than oxidative phosphorylation and therefore is preferred for some immune cells
as a quick source of energy, even if oxygen is abundant.
provides a reasonable gradation of D levels across healthy, aseptic, and septic outcomes.
Damage production increases in a saturating way with half-activation xdn. We assume
that healing occurs at a rate of µd and also requires energy. For simplicity we neglect any
contributions of phagocytes to clearing damaged tissue and assume that only Ab fuels healing.
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Equation (4) describes the dynamics of the anti-inflammatory mediators CA as in [61],
with terms for a baseline anti-inflammatory level sc, the promotion of anti-inflammatory
release by N and D, and an intrinsic decay term. We make the modification, however,
that CA release related to activated phagocytes and tissue damage depend on An and Ab,
respectively.
We define a rate function for production of Ax, where x stands for each of the subindices
b and n, as a decreasing sigmoidal function c(Ax). This phenomenological term represents
a ramping up of energy production when supplies diminish, [6]. It multiplies a sum of an
aerobic respiration (pyruvic pathway) component f (X/X∗) (1−λgx), downregulated by NO,
[15, 55], and an anaerobic respiration (glycolysis) term λgx. Because about 30 molecules of
ATP are produced per molecule of glucose in the aerobic pathway, while only 2 molecules of
ATP are produced in glycolysis, we estimated λgb in such a way that (1−λgb)/λgb = 15. On
the other hand, unlike the majority of cells in the body, phagocytes rely on ATP production
from mostly the anaerobic pathway. For this reason, we estimated λgn = 0.9.
The Ax equations include sums of energy flux terms Φi that represent all of the processes
in the model that consume energy and hence deplete the level of Ax. Specifically, phagocyte
production/activation and migration of phagocytes to the infected area are all processes that
require An and are represented in Φ3. Note that even though energy dependence arises in
the final terms of both equations (1) and (2), these terms derive from the effects of the same
process, phagocytosis. For this reason, the single flux term Φ2 accounts for both of these
terms. An is also consumed in the production of anti-inflammatory mediators by phagocytes
in equation (4), represented by Φ5. Similarly, Ab is consumed by non-specific pathogen
elimination and production of anti-inflammatory mediators as well as in healing and cellular
regeneration. Corresponding terms appear in equations (1), (3), and (4) and these effects
are captured in the flux terms Φ1,Φ4,Φ6. We assume that both ATP supplies are naturally
depleted at a constant rate of µA and in the absence of infection both reach an equilibrium
level at 1.
The production of NO, denoted by X, is driven by tissue damage and by activated
phagocytes via induction of iNOS through pro-inflammatory cytokines, such as IL−1β, IL−2,
IL−6, TNF and IF−γ, [46]. The former process is included in the knodD term while the latter
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process motivates the knonN term in the production of NO in equation (7). This production is
modulated by anti-inflammatory mediators, such as IL-10 and IL-8, represented in equation
(7) with the factor f(CA/C
∗). Nitric oxide is assumed to be naturally depleted at a rate of
µno .
Lactate, denoted by L, is generated in anaerobic glycolysis. In the absence of oxygen,
glucose is metabolized into pyruvate generating lactate as a byproduct. Equation (8) was
constructed such that the greater the inhibition of cellular respiration through NO, the more
lactate is produced. Finally, lactate is assumed to be naturally depleted at a rate of µL.
Lactate will play an important role in our model as there is available data of lactate for
septic patients.
Some of the parameters in our model were extracted from existing literature as shown in
Table 2. However, the remaining parameters were tuned to achieve biologically reasonable
behavior. For instance, all the state variables must remain positive. Also, some processes are
known to require more energy than others, and the parameters involved in the energy fluxes
were estimated accordingly. Moreover, nitric oxide is known to have rapid dynamics [76] and
ATP production depends on two different pathways with different production rates. All of
these considerations were taken into account when tuning the model parameters. Most of
these parameters are dimensionless since the variables represented by the model are assumed
dimensionless as we are concerned here with qualitative behavior of the system rather than
fitting specific data sets. The system of equations (1)-(8) was solved numerically using ode23s
in Matlab R2018a. We choose this solver to avoid issues with stiffness and accuracy; results
with ode45 were similar (data not shown).
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Table 1: Parameter values
Parameter Range Value Description Sources
kpg 0.021-2.44/h Varies Pathogen growth rate [69], [77]
P∞ Estimated 20× 106/cc Carrying capacity for pathogen Vodovotz, Y.
pers. comm.
kpm Estimated 0.002 Rate parameter for the elimination of
pathogens by the non-specific local response
kns Estimated 0.25 Weighting of the energy-dependent component of
non-specific pathogen elimination
µm 0.0013–0.0048/h 0.002/h Half-activation parameter for the non-specific local response [44]
kmp Estimated 0.1 Saturation rate parameter for the non-specific local response
kpn Maximum 2.5/N - 0.75 Phagocytosis rate [10]
units/h
C∗ Estimated 0.17 Saturation parameter for effects [42]
of anti-inflammatory mediators
kps Estimated 0.3 Phagocytosis saturation constant
snr Estimated 0.16 Production rate for activated phagocytes
(based on resting phagocyte level [61])
knn Estimated 0.007 Weighting of contribution to activation of resting phagocytes
by previously activated phagocytes and their cytokines
knp Estimated 0.5 Weight of contribution to activation of resting
phagocytes by pathogen
knd Less than knp 0.03/h Weight of contribution to activation of resting [2]
phagocytes by tissue damage
µnr 0.069-0.12/h 0.1/h Decay rate of resting phagocytes [61] [22]
µn Less or equal than µnr 0.1/h Decay rate of activated phagocytes [22]
kde Estimated 0.75 Pathogen degradation enhancement constant
kdn Estimated 0.0037 Maximum rate of damage produced
by activated phagocytes
xdn Estimated 0.14 Determines levels of pathogens and nitric oxide needed
to bring damage production up to half its maximum
µd Estimated 0.01/h Decay rate of damage
sc Estimated 0.0625 Source of anti-inflammatory mediators [80]
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Table 2: Parameter values continued
Parameter Range Value Description Sources
kcn Estimated 0.02 Maximum production rate of anti-inflammatory mediators
kcnd Estimated 48 Effectiveness of damaged tissue relative to activated phagocytes
in inducing production of anti-inflammatory mediators
µcq Estimated 1 Determines the levels of activated phagocytes and damage that are needed to bring
rate of anti-inflammatory mediator production to half its maximum
µc 0.15-2.19/h 1/h Decay rate of anti-inflammatory mediators [3], [8]
[34], [41]
µA Estimated 0.1 Baseline depletion rate of both ATP supplies
cg Estimated 1 Half-saturation energy level for
the driving of various processes
k1 Estimated 3 Phenomenological energy production parameter
k2 Estimated 0.01 Phenomenological energy production parameter
c1 Estimated 0.03 Energy consumption rate of Φ1
c2 Estimated 0.015 Energy consumption rate of Φ2
c3 Estimated 2.25 Energy consumption rate of Φ3
c4 Estimated 4 Energy consumption rate of Φ4
c5 Estimated 0.05 Energy consumption rate of Φ5
c6 Estimated 0.05 Energy consumption rate of Φ6
knon Estimated 3 Rate of NO release due to presence
of pro-inflammatory cytokines
knod Estimated 0.1 Rate of NO release due to tissue damage
µno Estimated 1 Natural depletion rate of NO
X∗ Estimated 0.5 Half saturation level of NO
λL Estimated 0.5 Production rate of lactate
µL Estimated 0.05 Decay rate of lactate
λgb Estimated 0.0625 Fraction of Ab produced via the anaerobic
pathway in the absence of NO
λgn Estimated 0.9 Fraction of An produced via the anaerobic
pathway in the absence of NO
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2.3 Fundamental asymptotic states and multi-stability
The system of equations (1)-(8) exhibits three biologically significant long term outcomes.
The outcome that allows host survival, the healthy state, occurs when the immune system is
able to completely eliminate the pathogen and there is resolution of inflammation. When the
immune system satisfactorily eliminates the insult but in the process, a sustained immune
activation occurs, leading to persistent inflammation and tissue damage, the patient is said
to be in aseptic state. In this case, multiple organ dysfunction syndrome (MODS) may
occur, followed eventually by death. The third and possible outcome, the septic state,
occurs when a massive influx of pathogens attacks the host or when the pathogen growth
rate is overwhelming. The immune response of the infected individual cannot wipe out the
pathogen, leading to sustained presence of pathogen along with persistent inflammation,
tissue damage, lactate accumulation, organ dysfunction and eventually death.
Representative time courses of these outcomes appear in Fig. 3, the pathogen growth
rate kpg was chosen to achieve the various states, while the initial conditions were identical
and all other parameters are kept at the values reported in Table 2. In the healthy case
(Fig. 3a), as a response to the initial insult, there is a surge in N as phagocytes become
activated and travel to the infected area to eliminate pathogens. This process induces tissue
damage, represented by a rise in D, and a release of anti-inflammatory mediators, given by
an increase in CA. Both NO and lactate levels also increase, while energy supplies drop
below baseline due to enhanced energy consumption associated with all of these processes.
The model suggests that the patient would eliminate the pathogen and that subsequently,
the levels of ATP and all other inflammatory indicators would return to baseline.
In the aseptic case (Fig. 3b), a similar set of processes begins in response to the ele-
vated pathogen level. In the example shown, despite the initial inflammatory response, the
pathogen population size grows before subsequently decaying. The elimination of pathogen
requires a greater surge in the components of the inflammatory response and a correspond-
ingly more substantial reduction in energy levels. Interestingly, although phagocyte activity
causes a decrease in An, the drop in Ab, associated with the baseline immune response and
various tissue damage and healing effects including CA production, is even more pronounced.
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Although the immune response eventually eliminates the infection and energy levels rise
again, the associated elevation of phagocyte activation and pro-inflammatory effects cannot
be fully countered by the anti-inflammatory mediators. In the long term, N tends to a
non-zero value, D continues to grow, levels of both ATP pools remain below baseline, and
sustained accumulation of both NO and lactate occurs. This sustained damage and other
effects would be expected to cause organ dysfunction and death in patients.
The septic case also starts with a rise in levels of pathogen and immune agents (Fig. 3
c). As anti-inflammatory mediators accumulate, they cause mild reductions in N , X, and L,
but P and D continue to rise. Energy levels fall and exhibit little (Ab) or no (An) recovery.
Without elimination of pathogen, all immune components tend in the long term to elevated
levels, with sustained energy depletion, which in patients would together result, as in the
aseptic case, in severe tissue damage, organ dysfunction and death.
The example trajectories shown demonstrate clear relations between N , X, L, and both
Ab and An. The presence of pathogens activates neutrophils, which leads to NO and lactate
production. These three responses are clearly inversely proportional to ATP levels relative
to baseline, or directly proportional to ATP consumption. High demand for neutrophil
activation and other pro-inflammatory effects consumes large amounts of energy. In general
we observe a strong relation between ATP levels and long term outcomes.
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(a) (b) (c)
Figure 3: Transient behavior of model (1)-(8). Three outcomes are illustrated: (a) health,
obtained by taking kpg = 0.01, (b) aseptic, with kpg = 0.08, and (c) septic, with kpg =
0.1. The initial conditions in all three cases were identical: P (0) = 1, N(0) = 0, D(0) =
0, CA(0) = 0.0625, Ab(0) = 1, An(0) = 1, X(0) = 0, L(0) = 0. Values for parameters other
than kpg are given in Table 2. 17
Each of the outcomes illustrated in Fig. 3 corresponds to an equilibrium point of system
(1)-(8), as characterized in Table 3.
Table 3: Biologically significant equilibrium points
Name Equilibrium Point
Health (P = 0, N = 0, D = 0, CA > 0, Ab = 1, An = 1, X = 0, L = 0)
Aseptic (P = 0, N > 0, D > 0, CA > 0, 0 < Ab < 1, 0 < An < 1, X > 0, L > 0)
Septic (P > 0, N > 0, D > 0, CA > 0, 0 < Ab < 1, 0 < An < 1, X > 0, L > 0)
We performed a bifurcation analysis of the model using XPPAUT ([31]) to explore more
thoroughly the relations among these equilibrium points with respect to variations in the
pathogen growth rate kpg. Results are shown, projected onto the variables P , N , Ab, and
An, in Fig 4, where stable equilibrium curves are presented as solid, unstable as dashed, and
additional non-physiological bifurcation curves (e.g., with values for one or more variables
negative) are not shown.
The healthy and aseptic equilibria, characterized by P = 0, both exist for kpg = 0
and persist, with no change in equilibrium values of P,N,Ab, and An as kpg increases.
For sufficiently large kpg, each of these equilibria loses stability by meeting an unstable
equilibrium state in a transcritical bifurcation. These occur at kpg = 1.125 and kpg = 1.143,
respectively; besides the destabilization of the healthy and aseptic states, these result in
the previously unstable equilibria becoming stable but non-physiological (not shown). Well
before these destabilizations, at kpg = 0.048, the stable septic equilibrium point arises,
along with an unstable equilibrium state, through a fold bifurcation. In fact, this unstable
equilibrium is the same one that eventually participates in the transcritical bifurcation that
destabilizes the aseptic state. Unlike the other two equilibria, the coordinates of the septic
equilibrium do depend on kpg, although they do already approach asymptotic values at
relatively low kpg.
Putting these results together, we observe that while the healthy and aseptic are bistable
for 0 < kpg < 0.048, the model exhibits tri-stability for 0.048 < kpg < 1.125. Once the healthy
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state loses stability, bi-stability between the septic and aseptic equilibria persists over the
small range 1.125 < kpg < 1.143. Our model shows similar structure to the model presented
in [61] in the sense that they both have the same three biologically relevant equilibrium
points. Although the bifurcations of health and asepsis for our model occur for slightly
lower values of kpg than in the earlier work, the values are fairly close. On the other hand,
the fold bifurcation introducing the septic state in our model occurs at a much smaller kpg
value than in [61].
This bifurcation analysis confirms that our model consistently exhibits a strong relation
between low levels of ATP and sepsis. Similar results have been observed in human data, [12].
In particular, in Fig. 4c and Fig. 4d, we note that during sepsis, Ab attains an equilibrium
at 0.62 while An drops to a new equilibrium at 0.73. The model analysis also verifies that
accumulation of lactate and NO occurs during sepsis in general, although the projections of
the bifurcation diagrams to these variables are not shown.
The bifurcation analysis shows that for our baseline parameter set, it is possible to
choose the pathogen growth rate, kpg, at a value for which either two or three physiologically
relevant equilibrium points exist and are stable. For such a parameter set, different model
trajectories will converge to different equilibria, selected by the choice of initial conditions
for the model variables. In particular, by simulating model behavior over a long time period
for each of a grid of values of kpg and P (0) (denoted by P0), with all other parameters
and initial conditions fixed, we can numerically explore how predicted outcome depends on
the intensity of the pathogenic invasion. This simulation defines a basin of attractions for
each type of equilibrium, defined as the set of (kpg, P0) for which the resulting trajectory
converges to that equilibrium state. Fig. 5 displays the partitioning of the (kpg, P0) plane
into basins of attraction resulting from this experiment. Note that the tristability observed
in the bifurcation analysis here corresponds to the existence of a range of kpg values at which
a vertical line through the plot would intersect all three basins.
In the bifurcation diagram, asepsis looses stability at kpg = 1.143, while in the basin
of attraction, asepsis seems to disappear at about kpg = 0.2. This apparent contradiction
occurs because the basin of attraction and the bifurcation diagrams are obtained through




Figure 4: Bifurcation diagrams for the system of equations (1)-(8). Equilibrium states
are illustrated with solid red curves (stable), shown with dashed curves (unstable), or not
shown at all if non-physiological. The three stable equilibrium points correspond to healthy,
aseptic, and septic states. Health loses stability at a transcritical bifurcation at kpg = 1.125.
The aseptic state loses its stability at a transcritical bifurcation at kpg = 1.143. At kpg =
0.048, a fold bifurcation gives rise to the septic equilibrium point. (a) Bifurcation diagram
for P versus kpg . Here both healthy and aseptic equilibrium points coincide at P = 0.
(b) Bifurcation diagram for N versus kpg. (c) Bifurcation diagram for Ab versus kpg. (d)
Bifurcation diagram for An versus kpg. All parameters other than kpg are as in Table 2.
model on a grid of values of kpg and P0 and with the remaining initial conditions fixed at
baseline levels. On the other hand, the bifurcation diagrams are found by studying the
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eigenvalues of the jacobian of the system (1)-(8). More precisely, the initial conditions do
not play a role in the classification of equilibrium points, but they do in the computation of
the basins of attraction. What the bifurcation diagram suggests is that there must be some
initial conditions where asepsis exists and is stable for kpg ∈ (0, 1.143).
The basin of attraction results are not as exact as the bifurcation analysis because they
are based on simulations with finite time horizons, which may yield faulty conclusions in
borderline cases in which pathogen are eliminated only after extremely long time periods,
and because they are limited to a finite range of P0 values. Nonetheless, they represent a
valuable complement to the bifurcation analysis. They show, for example, that values of P0
needed to produce septic outcomes for low kpg (e.g., < 0.06) are relatively quite high (e.g.,
> 2), well above the level where healthy outcomes are no longer possible. This diagram
is also useful in that it represents a prediction of the outcome of a standardized patient,
characterized by our baseline parameter set and baseline initial conditions for all variables
other than P , when exposed to a pathogen for which the growth rate and initial load are
known.
2.4 Model application to altered metabolic states
Some altered metabolic states such as hypoglycemia, hyperglycemia, and hypoxia have been
found to compromise the performance of the immune response against infection. With small
variations our model can be used to study these three energetically dependent conditions. We
compare the performance of our model with existent literature about the relation between
these three conditions and sepsis.
Hypoglycemia is defined as low blood glucose or low blood sugar. Insufficient glucose in
the blood will compromise the production of ATP and as a consequence it will reduce the
effectiveness of the immune system in fighting the infection. Hyperglycemia, also known as
high blood glucose, activates protein kinase C, which inhibits neutrophil activities such as
migration, phagocytosis, apoptosis, and killing of microbes. Finally, hypoxia is characterized
by the lack of the necessary oxygen to accomplish metabolic requirements. When an inad-
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Figure 5: Basins of attraction of healthy (H), aseptic (A), and septic (S) equilibria for
equations (1)-(8). The healthy region is bounded by the coordinate axes and the solid blue
curve, the aseptic region lies between the solid blue and red curves, and the septic region is
above the red solid curve. All the parameters and initial conditions except kpg and P0 were
taken as in Table 2 and Fig. 3.
equate amount of oxygen reaches the tissues, cellular respiration (production of ATP) must
rely more heavily on anaerobic glycolysis. Also, pro-inflammatory cytokine levels increase,
causing inflammation and tissue damage during hypoxia.
2.4.1 Hypoglycemia
It seems natural to suggest that hypoglycemia in vivo involves a decrease in glucose produc-
tion, an increase in glucose demand, or both. Possible factors contributing to hypoglycemia
include depletion of glycogen stores, impaired gluconeogenesis and increased peripheral glu-
cose utilization, [54]. In a study performed in rats by [48], it was found that during sepsis
there is an increase in glucose utilization by macrophage-rich-tissues that could lead to hy-
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poglycemia.
Several studies have been conducted to understand the relation between hypoglycemia
and sepsis. In a study performed on nine human patients, [54] observed that hypoglycemia
was associated with overwhelming sepsis. In fact, in four of these patients, sepsis was the
only cause of hypoglycemia. In five patients, another possible cause for hypoglycemia was
present (alcoholism and chronic renal insufficiency). All patients exhibited metabolic and/or
respiratory acidosis. Although serum lactate was not measured, their metabolic acidosis was
presumably secondary to lactate accumulation.
Because our model does not contain an equation for glucose, but glucose is the fuel for
ATP production, we indirectly represented the effects of hypoglycemia by a reduction in the
rate of ATP production in equations (5)-(6). As we observed in our bifurcation analysis,
the state variables An and Ab are always between 0.6 and 1. One can easily check that the
behavior of the function c(Ax) is mostly governed by the parameter k1 in this range of Ax.
Therefore, to lower the ATP production rate, we decreased the control parameter k1, which
resulted in reduced An and Ab levels. Lowering Ab availability affects the healing process
as well as the production of anti-inflammatory cytokines and the response of nonspecific
immune cells. On the other hand, reducing An impacts the production and activation of
neutrophils, undermines pro-inflammatory cytokine production, and slows phagocytosis.
Several studies have also found that hypoglycemia increases leukocytes and circulating
pro-inflammatory cytokines, [56, 60]. To include this effect, we also increased the parameter
snr, which controls the rate of phagocyte production, by 25%. Combining this change with
the alteration in k1, we found the same three physiological equilibria as in our baseline case
and we recomputed the basins of attraction for these states.
As a result of the pro-inflammatory and energy effects of hypoglycemia, the lower bound-
aries of the basins for both the septic and aseptic equilibria shifted to smaller P0 values, at
the expense of healthy and aseptic territories, respectively (Fig. 6). The shift from health to
an aseptic state was particularly pronounced for small kpg. The shift from aseptic to septic,
on the other hand, took the form of a translation of the boundary between the two outcomes
to a lower kpg level, fairly uniformly in P0. In general, our results agree with the findings
of [54] that hypoglycemia promotes sepsis, while providing a more detailed specification of
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how outcomes of pathogen invasion under hypoglycemia are predicted to depend on invasion
characteristics.
Figure 6: Basins of attraction for hypoglycemic versus normal states. The dashed blue
and red lines correspond to the baseline boundaries distinguishing aseptic from healthy and
septic outcomes, respectively, as shown in Fig. 5. The blue and red solid lines indicate the
new boundaries in the presence of hypoglycemia. The arrows highlight the direction of the
shift that occurs with hypoglycemia induction. To represent hypoglycemia, we took k1 = 1,
snr = 0.2, and all remaining parameter values are as in Table 2.
2.4.2 Hyperglycemia
Septic patients may become hyperglycemic due to a combination of various factors. For
instance, they may experience increases in insulin clearance, causing a reduction in insulin-
mediated glucose uptake. Septic patients may also develop hyperglycemia due to adverse
effects of certain therapies such as glucocorticoids or sympathicomimetic drugs. Additionally,
insulin resistance, which is proportional to the severity of the stress response, also promotes
hyperglycemia, [52].
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Although hyperglycemia might naively be expected to benefit the inflammatory response
by providing extra fuel to support pathogen elimination, it has in fact been found to have
negative impacts on acute immune-related outcomes. In particular, in a study conducted
on 62 patients with severe sepsis, [49] found that stress hyperglycemia is related to high
elevated cytokine levels (IL-6 and TNF-α) and the severity of the disease. Moreover, it is
known that hyperglycemia increases vascular permeability as well as inflammatory cytokine
levels, altering the balance between anti-inflammatory and inflammatory cytokines in a way
that might promote run-away inflammation. It also increases neutrophil adherence, which
inhibits cellular migration at sites of inflammation. Finally, hyperglycemia can actually
suppress neutrophil activity including metabolism, phagocytosis and microbial killing. These
effects could lead to an increase in infection intensity and cause tissue damage, [43].
To simulate a hyperglycemic state in a simple way with our model, we decreased the rate
of phagocytosis and microbial killing by 25%, setting kpn = 0.5625. Similarly, we reduced
parameters associated with phagocyte recruitment and metabolism, decreasing their pro-
duction and depletion rates by 15%, setting snr = 0.136 and µn = 0.085; the choice of 15%
rather than 25% here was made to represent compensation due to increased vascular perme-
ability. Together, these changes not only slow down the immune system response but they
also more generally affect the subsequent time course of inflammation. Interestingly, these
changes lead to somewhat similar shifts in basins of attraction as occur with hypoglycemia,
namely shrinking of the healthy region and a shift in the aseptic region to lower kpg levels;
see Fig 7. Our model predicts milder effects of hyperglycemia than hypoglycemia, however;
specifically, the extent of the septic region does not change as significantly in hyperglycemia
and the change in the aseptic basin at small kpg is milder. Nonetheless, our model agrees
with the literature suggesting that hyperglycemia promotes sepsis, again with detail about
possible dependence on pathogen properties.
2.4.3 Hypoxia
Hypoxia-induced inflammation and inflammation during hypoxic conditions in the context
of several human diseases have been studied in a variety of recent publications, [29]. For
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Figure 7: Basin of attraction for hyperglycemic versus normal states. The dashed red and
blue lines indicate the septic and healthy boundaries in the baseline scenario shown also in
Fig 5. The solid red and blue lines indicate the boundaries with the introduction of hyper-
glycemia. The arrows indicate the direction of the transition. To represent hyperglycemia,
we set snr = 0.136, µn = 0.085, and kpn = 0.5625. All the other parameters were taken as in
Table 2.
instance, people with mountain sickness have exhibited increasing levels of pro-inflammatory
cytokines as well as pulmonary or cerebral edema, [64, 38, 35]. In another study, healthy vol-
unteers experienced higher levels of IL-6 and other pro-inflammatory cytokines after spend-
ing 3 nights at an elevation above 3400 m, [39]. Also, studies in mice have found that after
short-term exposure to low oxygen concentrations, vascular leakage, accumulation of inflam-
matory cells and high levels of cytokines occur [29]. Further, ischemia and reperfusion injury
have been associated with inflammatory responses that lead to subsequent organ dysfunction
[30, 5].
We represented the pro-inflammatory effects of hypoxia in our model by increasing the
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parameter snr by 12.5%. Moreover, the reduced oxygen availability was addressed by intro-
ducing a new parameter 0 < εH < 1 and replacing f (X/X
∗) by εHf (X/X
∗) in equations
(5), (6) and (1− f (X/X∗)) by (1− f (X/X∗))εH in equation (8). Recall that equation (8)
represents enhanced lactate production due to diminished function of the aerobic pathway
with rising X. The latter adjustment therefore implements a decrease in this additional
lactate production, since for each X, the aerobic pathway is less active under hypoxic than
control conditions.
As a result of these modifications, as seen in Fig. 8, the basin of attraction of the healthy
state shrinks, making the aseptic outcome more likely. On the other hand, the septic region
hardly changes in the presence of hypoxia, suggesting that hypoxia does not promote sepsis.
This outcome is natural because the lack of oxygen does not affect An, which is the energy
needed to produce inflammation. It does cause a reduction in the supply of Ab, however,
which is the energy needed for healing and anti-inflammatory cytokine production, such that
an over-exuberant pro-inflammatory response can result. These results are also consistent
with the observations in a previous computational model that for low values of kpg, such
reduction in anti-inflammatory cytokines promotes aseptic outcomes [61].
In general, our results suggest that maintaining patients blood sugar within an euglycemic
range might be beneficial for recovery from sepsis as long as the pathogen load and pathogen
growth rate are under moderate levels as well. Also, regulating oxygen delivery improves the
chances of recovery as long as the patient is in aseptic state.
2.4.4 Survival analysis
So far, we have discussed results of a variety of simulations using our baseline parame-
ter values given in Table 2 with variations in kpg and P0, as well as some outcomes from
modifications of a few specific parameters designed to represent effects of certain altered
metabolic states. A more realistic situation would be to consider a heterogeneous collection
of parameter sets, representing the variability inherent in actual patient populations.
We adopted this heterogeneity to generate predictions about survival rates among a
population of 300 virtual patients. We introduced variability in those parameters on which
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Figure 8: Basin of attraction for hypoxic versus normal states. The dashed blue and red
curves indicate the healthy and septic boundaries for the baseline case as shown in Fig. 5.
The solid blue and red curves indicate these boundaries in the presence of hypoxia. The
arrow indicates the direction of the transition. To obtain hypoxia we take snr = 0.18 and set
the new parameter εH = 0.5 (see text), which diminishes the output of the aerobic pathway
for energy production. All other parameter values were taken as in Table 2.
we found that the model outcomes depended most sensitively. Specifically, we determined
the set of most sensitive parameters in the model by computing the relative sensitivities
(∂x(t)/∂θ)(θ/x(t)), where x(t) corresponds to the vector of state variables and θ is the
vector of parameters. The healthy state was taken as a baseline for generating x(t), which
included the variables P,N , and D. Choosing a sensitivity threshold of 0.09, we obtained
the following subset of sensitive parameters:
kpg, kpm, kmp, kpn, snr, knp, knd, µn, kdn, µd, sc, µc, c3, µA, C
∗, k1 (9)
In addition to these, we also included variability in the initial levels of anti-inflammatory
mediators, CA0 , and the pathogen load, P0. Therefore, to generate each virtual patient, a
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total of 16 parameters and two initial conditions were perturbed randomly from their baseline
value given in Table 2. We let kpg and P0 be uniformly distributed on the intervals [0, 0.2]
and [0, 0.45], respectively, so that the outcomes of simulations of virtual patients were not
driven primarily by pathogen-dependent parameters but by the parameter set as a whole.
On the other hand, the remaining parameters, including the initial condition CA0 , were taken
to be normally distributed around their baseline values with a standard deviation of σ = 0.2
relative to the size of each parameter with the exception of k1, for which we used a smaller
standard deviation of σ = 0.03 so that every patient would have relatively similar energy
availability as the baseline level defined by the parameters in Table 2.
After producing our population of 300 virtual patients, we simulated the time courses
of their inflammatory responses until they clearly approached one of the model equilibrium
states, healthy, aseptic, or septic. Each virtual patient was assigned an outcome based on
its asymptotic behavior. Fig. 9 depicts the outcomes, projected to the plane of the patients’
P0 and kpg values. Note that, while lower (higher) kpg and P0 are naturally associated with
more healthy (septic) outcomes, outcomes were certainly not dictated by this parameter pair
but rather were intermingled in many regions of the plane. Of the model patients, 60.7%
were classified as healthy, 19% as aseptic, and 20.3% as septic.
For those patients with aseptic and septic outcomes, we used our model to assign each
a time of death. To do so, we considered levels of lactate and damage, which are associated
with appraisals of patient status in clinical settings. Based on comparisons across long-
time simulations, we determined that the maximum observed damage provided the most
reliable separator between patients with healthy outcomes, or survivors (n = 182), and
other patients, or non-survivors (n = 118). Specifically, we found that for all 300 virtual
patients, D(t) < 0.30635 for the full simulation time if and only if the patient was in the
survivor group. Thus, we defined the time of death of each non-survivor patient be the
moment when the damage trajectory hits 0.30635 units. As one can notice from Fig. 10,
the same separation would have also resulted from using any other value between 0.30635
and 0.5 as the designated damage threshold. Based on the damage threshold, we plotted the
fraction of patients classified into each outcome group and of the total population that were
still alive, with damage not yet exceeding threshold, as a function of time (Fig. 11a). The
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surviving fraction among septic patients dropped faster than among aseptic patients, with
full loss of survival before 350 hours.
Finally, we explored how the conditions of altered metabolism discussed in subsection
2.4 affected survival trajectories among virtual patients. For each condition, we created a
new group of virtual patients. To do so, we started from the baseline population we had
already generated and we modified parameters in a way that was consistent with the desired
condition. Specifically, to represent hypoglycemia in the population, we decreased k1 by
66.67% for each patient and we increased each patient’s snr value by 25%. As a result, the
percentage of healthy patients dropped to 50.3%, the aseptic population size decreased to
23%, and the septic population fraction increased to 26.7%. As shown in Fig. 11b, the aseptic
hypoglycemic patients die at similar rate than in the normal (euglycemic) case, except that
a tail of longest surviving patients is lost. Due to the enhanced pro-inflammatory effects and
the lack of energy associated with hypoglycemia, the hypoglycemic septic patients die at a
faster rate than the euglycemic ones. The overall acceleration of death by hypoglycemia can
also be observed in Fig. 11b, where combined survival curves are displayed.
Next, we induced hyperglycemia in the virtual patients by reducing their kpn values
by 25% and both snr and µn by 15%, just as we did to represent hyperglycemia from our
baseline parameter set. As a result, the percentage of healthy patients was reduced to
56.3%, the aseptic population decreased slightly to 17%, and the septic population increased
to 26.7%. The survival curves of the virtual hyperglycemia population are shown in Fig
11c. When looking individually at the septic population, it is difficult to distinguish a
significant difference between hyperglycemic and euglycemic death rates. The hyperglycemic
aseptic population however dies at a faster rate compared to the euglycemic population and
consequently the tail of longer survival patients dies out sooner again. The overall death
rate in the population of hyperglycemic patients is indeed faster than in the euglycemic
population, however (Fig 11c).
In general, our model suggests that hypoglycemic septic patients die at a faster rate than
the hyperglycemic and euglycemic patients. In particular, in Fig. 12a we show the overall
survival curves for the 4 populations (euglycemic or healthy, hypoglycemic, hyperglycemic,
and hypoxic) for a period of 15 days. Here, we have shifted the x-axis so that day 0 starts at
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the 55 hour time point from the other panels, which is about the time the virtual patients
start to die. For model validation, we compared the qualitatively behavior obtained in our
simulations with a study performed in 418 Ugandan patients with severe sepsis, where 16.3%
of the patients were diagnosed as hypoglycemic and 50.2% as hyperglycemic. Among these
patients, the hypoglycemic cohort died at a faster rate than the hyperglycemic patients and
both died faster than the euglycemic patients, [70]. The survival curves of the euglycemic,
hyperglycemic, and hypoglycemic patients in this study are reproduced in Fig. 12b and their
results are consistent with our simulations shown in Fig. 12a.
To finish, we represented hypoxia among the virtual patients by increasing the inflamma-
tory parameter snr by 12.5% and set εH = 0.5 to represent a 50% reduction of oxygenation.
As a result, the percentage of healthy individuals dropped to 53%, the aseptic population
size increased to 28%, and the septic component decreased slightly to 19% of the population.
These results are consistent with what we observed in the basins of attraction in Fig. 8:
hypoxia promotes the aseptic state and diminishes health, with relatively little impact on the
likelihood of septic outcomes. The survival curves for the hypoxic population are depicted
in Fig. 11d. Here we observe that hypoxic patients with sepsis die at a faster rate than
non-hypoxic septic patients and overall, hypoxic non-survivors die faster than non-survivors
in the non-hypoxic group.
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Figure 9: Representation of outcomes for a population of 300 virtual patients on kpg versus
P0 plane.
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Figure 10: Representation of outcomes for a population of 300 virtual patients on the kpg
versus max D plane. Projection with respect to P0 and the maximum damage value attained
over the course of patient simulation. The solid gray line indicates the threshold of 0.30635




Figure 11: Survival curves of the 300 virtual patients across metabolic conditions. (a)
Baseline euglycemic or normal population. (b) Hypoglycemic population. (c) Hyperglycemic
population. (d) Hypoxic population. The red solid lines show fraction surviving from the
septic group, the green correspond to the aseptic group, and the blue combines healthy,
septic, and aseptic subjects.
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(a) (b)
Figure 12: (a) Survival curves of the total euglycemic, hypoglcemic, and hyperglycemic
virtual patient populations. The 15 day time courses shown correspond to the range from
55-415 hours of the virtual population simulation shown on Figures 11(a)-(d). (b) Data from




In this chapter, we present a reduced model system that describes the dynamics of the
immune system in the presence of pathogens and incorporates energy production along with
the energy requirements that arise in fighting such an infection. To the best of our knowledge,
this is the first model that incorporates these features. This model builds on several previous
models representing various aspects of the acute inflammatory response [61], [47], [19], [26],
[24], [57]. In addition to two ATP components, our model includes an equation for lactate,
which can be measured experimentally in patients and thus will allow us to fit the model to
data in future work.
From the point of view of dynamical systems, the model presents an interesting bifur-
cation structure with respect to variations in kpg. In particular, tri-stability among healthy,
aseptic, and septic states can be achieved for fixed values of kpg, as in previous models [61],
which reflects a realistic tuning in that the same patient could end up in any one of these
three states, depending on infection severity. While bifurcation analysis indicated which
equilibrium states are present and over what ranges of kpg they are stable, we also consid-
ered the basins of attraction of these states, which indicated the practical relevance of the
available stable equilibria in terms of the levels of P0 needed for them to emerge.
Our results show that both the energy supply to phagocytes and that to other cells in
the body play fundamental roles in sepsis. As an infection progresses, the high level of ATP
usage associated with the inflammatory response drives augmented energy production as well
as a large accumulation of lactate, overproduction of NO, further inflammation, and tissue
damage, which in patients could lead to organ dysfunction and death. In general, all of these
findings are consistent with experimental data [12], [13], [14]. The inclusion of energy dynam-
ics in the model induced a reduction in the healing capacity of the inflammatory process due
to limitations on pro-inflammation, pathogen elimination, and healing of damage imposed
by energy consumption. Moreover, it allows us to simulate hyperglycemia, hypoglycemia,
and hypoxia and to explore their effects on the inflammatory response. In particular, the
immune consequences of hyperglycemia and hypoglycemia promote sepsis and make health
and recovery less likely. We also observed that hypoxia favors an aseptic outcome and does
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not have a crucial effect on sepsis. This result arises because the non-phagocyte related
energy demands in the model rely more on the aerobic ATP production pathway, whereas
the energy supply associated with phagocytes and pro-inflammation is more biased towards
the anaerobic route.
We created 300 virtual patients by introducing variability in a sensitive subset of model
parameters. We included heterogeneity in kpg among this virtual population to reflect the
reality that in any infected patient population, infections of disparate severities would be
represented. Based on outcomes arising in simulated infections, we subdivided our virtual
patient population into survivors and non-survivors. We predicted the times of death for the
non-survivors via a threshold that we defined based on the damage level in each simulated
patient.
The biological conclusions that can be drawn from our model are, however, limited by the
fact that the model is simplified and does not consider many other interactions that occur in
the immune system during infection. One of the weaknesses of the model is that it assumes
that values of all parameter are kept fixed through the entire time course of infection, which
is not entirely realistic. For example, with parameter variation over time, the model could
account for metabolic re-programming or the ability of tissue to survive by shutting down
non-essential function and thus decreasing damage, [66]. Another aspect of the model that
could merit refinement in future work is the definition of death. We defined time of death as
the moment when the D trajectory exceeded a certain threshold. However, the level of an
appropriate “death threshold” could not be derived directly from biological principles and
depends on the extent of variability that we included in the virtual population.
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3.0 A data-driven model of the role of energy in sepsis
3.1 Introduction
The work presented in Chapter 2 was purely theoretical and did not involve any data cal-
ibration. In this chapter we present a data-oriented model that builds up in the model
presented in chapter 2. The goal here is to extend our initial model to one that can be fitted
with available animal data and that can eventually be used to better understand the role of
energy in sepsis and that can help physicians to make more informed decisions when dealing
with septic patients.
This chapter is organized as follows. We start in Section 3.2 by describing the origin
and details about the available animal data. We continue in Section 3.3 with a complete
description of the extended model. Lastly, in Section 3.5, we present sample health, aseptic,
and septic trajectories, including parameter values and initial conditions.
3.2 Experimental data
In this section we present the experimental data that is used to develop our extended model.
This data was originally collected and studied by Schlag et. al in [62]. In this study, thirty-
three baboons of the species Papio ursinus were sedated and intravenously infused with
2×109 colony forming units per kilogram of Escherichia coli (E. coli) at the beginning of the
experiment over a period 2 hours. Subjects received fluid resuscitation (Ringer’s solution 10
ml/kg/h) and antibiotic therapy throughout the experiment (gentamycin 4mg/kg every 12
h).
Several measurements were taking for a lapse of 28 days. However, we are just inter-
ested in 5 of the observed variables: elastase (ng/mL), glucose (mg/dL), lactate (mmol/L),
lipopolysaccharides (pg/mL) (LPS), and nitrate (µmol/L).
Elastase is an enzyme secreted by neutrophils during inflammation. It can therefore
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be directly compared to the number of activated neutrophils. Glucose is the main source
of fuel to sustain any biological process. Lactate is a byproduct of anaerobic respiration
and it is produced by a process called fermentation. LPS are molecules found in the outer
membrane of bacteria. Therefore, LPS release occurs whenever bacteria membrane is broken
during pathogen elimination. Nitrate is a byproduct of nitric oxide. Units will be consistent
throughout this thesis and we will not explicitly indicate them on figures. All measurements
were taking in hours at times t1 = 0, t2 = 2, t3 = 4, t4 = 6, t5 = 11, t6 = 23, t7 = 35, t8 =
47, t9 = 72, t10 = 144, t11 = 672.
Originally the experiment was designed to investigate the therapeutic effects of a nitric
oxide synthase (NOS) inhibitor, NG-monomethyl-Larginine (L-NMMA), on septic shock
by comparing two groups: the placebo or non-treated group which corresponds to those
animals that where not given any therapy during the experiment and the treated group
which was administered with the NOS inhibitor. The NOS inhibitor treatment L-NMMA
began after hour 12 on 16 subjects and was continuously administered during 36 hours,
i.e. until hour 48 of the experiment. Animals were treated in accordance with National
Institutes of Health guidelines. The experimental protocol was reviewed and approved by
the Institutional Animal Care and Use Committee of Biocon Research Laboratories, Pretoria,
South Africa [62].
We further classified the 33 subjects into two more groups: the survivors are the group
of subjects that lived until at least the first 144 hours from the beginning of the experiment
and the non-survivors which were subjects who died before 144 hours. These two groups
will be labeled by their subject number assigned in the original experiment and preceded by
a capital S to indicate survivors or by NS to indicate they are non-survivors.
To account for different scales and high variability across the observable variables, we
take the natural logarithm of the measurements. In Fig. 13 we show the observable variables
of the 4 placebo survivor subjects S89, S90, S100, and S101, where we are plotting the time in
logarithmic scale for better visualization. Similarly, Fig. 14 depicts the data of the placebo
non-survivors, NS66, NS67, NS69, NS73, NS74, NS76, NS80, NS88, NS92, NS97, NS98, and
NS104. We considered subject S75 (not shown) to be an outlier as its measurements were
considerably different from the other subjects, in at least one of the observable variables
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that we are taking under consideration. Fig. 15 shows the data for the survivors that were
treated with the NOS inhibitor, S91, S93, S95, S99, S102, S103, S106, S70, S72, S77, S79,
and S83, whereas Fig. 16, shows the time series for the non-survivors that were treated,
NS68, NS71, NS78, NS94.
There is no apparent reason for the glucose rise in mostly every subject at times t = 35
hours, t = 47 hours, and t = 72 hours. Although it is not mentioned in the experimental
study, we conclude the subjects must had been fed at day 2. As the purpose of our study is
to understand how energy is consumed by the immune response, we are going to disregard
these three time points in glucose for every subject.
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Figure 13: Time series trajectories of the observable variables for the survivors non-treated
subjects. The x-axis is in logarithmic scale for better visualization. For this reason the time
at t = 0 is not shown. The y-axis contains the logarithm of the observable variables.
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Figure 14: Time series trajectories of the observable variables for the non-survivors non-
treated subjects. The x-axis is in logarithmic scale for better visualization. For this reason
the time at t = 0 is not shown. The y-axis contains the logarithm of the observable variables.
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Figure 15: Time series trajectories of the observable variables for the survivors treated
subjects. The x-axis is in logarithmic scale for better visualization. For this reason the time
at t = 0 is not shown. The y-axis contains the logarithm of the observable variables.
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Figure 16: Time series trajectories of the observable variables for the non-survivors treated
subjects. The x-axis is in logarithmic scale for better visualization. For this reason the time
at t = 0 is not shown. The y-axis contains the logarithm of the observable variables.
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3.3 Mathematical model
We present a data-driven model of the acute inflammatory response that also keeps track
of the energy demand and production that is needed during activation of the acute immune
response to fight an infection. This model extends our previous work [59] which is presented
in this thesis in Section 2.2. This extended model consists of 14 ordinary differential equations
which includes the interactions shown in Fig. 17. It includes variables that are normally
measured in the ICU in septic patients, such as elastase, lactate, nitrate, lipopolysaccharides
(LPS), and glucose. This model also includes pyruvate which brings more detail to the
modeling of the cellular metabolism process and finally, this model also takes into account
glycogen which corresponds to a storage form of glucose.
We recall, as mentioned in Section 2.2, that phagocytes including neutrophils, rely their
production of ATP mostly on the anaerobic pathway, whereas the majority of other cells
in the body produce their ATP with no special preference between aerobic or anaerobic
metabolism. For this reason we split ATP into two pools, one that corresponds to the ATP
produced by the phagocytes An, and other to the ATP produced by all the other cells in
the body, Ab. Similarly, pyruvate was also separated into two distinct pools, Yb and Yn,
corresponding to the pyruvate generated during the production of Ab and An, respectively.
We once again use the notation Ax and Yx, where x stands for the sub indices b and n.
Overall, the first eight equations (12)-(19), have the same structure than our previous
model. However, some modifications were made in equations (13), (14), (16), (17), and (19),
which we discuss next. The first change appears in equation (13) on which the production
of activated phagocytes depends on LPS rather than on P . This change improves our first
model in that the actual reason phagocytes become activated by the presence of pathogens
is due to the release of LPS when their membrane is broken after elimination by immune
cells. Another minor change occurs in equation (14), where we introduce the parameter αx
which works as a conversion unit between P and X.
More elaborated improvements appear in the description of the energy metabolism. Al-
though the ATP equations keep the same structure as before, consisting of three parts:
production, consumption, and natural depletion, a relevant change is observed in the pro-
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duction of Ax. This production term consist itself of two parts. The first part contains
the term β(YmaxYx)/(Ymax + Yx) with β < 1, which indicates the fraction of pyruvate that
enters the mitocondria during the aerobic pathway, and it is down-regulated by nitric oxide
through the term f(X/X∗). The second term given by λanc(Ax)G, corresponds to the ATP
produced via anaerobic respiration. The function c(Ax) is a sigmoide which ramps up as Ax
is consumed, leading to the need of metabolizing more glucose to fuel the energy demand.
Although phagocytes rely mostly their ATP production on anaerobic respiration, aerobic
respiration still occurs but at lower levels. This is indicated by the εn parameter in front of
the aerobic production term of An. The parameter λan is fixed equal to 100, and denotes
the fact that anaerobic respiration is 100 times faster than aerobic respiration. From our
previous discussion in Section 2.2, we know that about 30 molecules of ATP are produced
per molecule of glucose during the aerobic pathway, whereas only 2 molecules of ATP are
produced in the anaerobic pathway. More specifically, 1 molecule of glucose is transformed
into 2 molecules of pyruvate which yields 30 molecules of ATP, which justifies the use of the
constants 15 and 2 in front of each term of the production of Ax. The consumption of both
ATPs is determined by the energy fluxes Φ1, Φ2, Φ3, Φ4, Φ5, and Φ6 which preserve the
same structure and meaning as in the original model. Similarly, the ATP intrinsic decay did
not change from the previous model and is equal to µA for both ATP’s. It is important to
mention that just as in the model presented in Chapter 2, Ab = 1 and An = 1 are baseline
values by design.
The production of Ab and An depends on the parameters kb and kn whose role is to
balance the units between molecules of glucose and molecules of pyruvate. These parameters
are fixed but dependent on other parameters and initial conditions. We can find explicit
expressions for kb and kn by solving equations (16), (17), (24), (25), (23), (22) around the
healthy equilibrium. That is, when P = 0, N = 0, D = 0, Ab = 1, An = 1, X = 0, we find
the values of Yb, Yn, Gly, and G and substitute them in equations (16) and (17) to obtain
equations (10) and (11). The bars over the variables indicate they are at the steady state









sg(Ymax + Yn) + 15βεnYmaxYn
(11)
The first term of the Yx equations describe the fact that 1 molecule of glucose yields
2 molecules of pyruvate, both being controlled by the corresponding decreasing sigmoidal
function c(Ax). The second and third terms on the Yx equations, correspond to the amount
of pyruvate that is converted during the aerobic pathway into Ax and to the intrinsic natural
decay of Yx, respectively. We assume both pyruvates decay at a rate of µY .
The new variables Nit and LPS act as read outs of nitric oxide (X) and P , respectively.
Nitrate is produced at a constant source rate snit. It is also produced as a byproduct of
nitric oxide at a rate kno and naturally depleted at a rate µnit. As a result of damaged tissue,
bacteria make their way into the gut causing LPS leakage, which we assume happens at
a rate slps. Moreover, LPS is found in the outer membrane of bacteria and it is released
whenever pathogens are eliminated by phagocytes and nonspecific immune cells. This occurs
at a rate klps and is included in the second term of equation (21). Finally, LPS is naturally
depleted at a rate µlps.
Lactate is produced as a byproduct of anaerobic respiration and its production depends
on how strong the X inhibition is on the aerobic pathway, causing pyruvate to enter into
the fermentation process. The lactate equation is written in such a way that the higher the
inhibition of nitric oxide on aerobic respiration, the more lactate is produced.
Finally, glycogen is a form of energy storage and when needed is converted back into
glucose and vice versa. We include an additional equation describing this glucose-glycogen
dynamics. We assume glucose is converted into glycogen at a rate kgly, that glycogen is
transformed into glucose again at a rate µgly, and we assume this transformation increases
when inflammation occurs. Glucose is assumed to be constantly produced at a rate of sg
and when glucose is not converted into glycogen it is used as fuel to produced ATP.
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Figure 17: Interactions between the variables appearing in the system of equations (12)-(25).
P denotes the level of pathogens, D corresponds to a marker of tissue damage, N represents
the level of active phagocytes, CA is anti-inflammatory mediators, X is nitric oxide, L lactate,
and An and Ab correspond to the levels of ATP produced by phagocytes and all other cells
in the body, respectively. Similarly, Yn and Yb, are the pyruvate levels for phagocytes and
other cells in the body, respectively. LPS measures the amount of lipopolysaccharides ,
Nit is nitrogen, G glucose, and Gly corresponds to glycogen. Arrows and bars indicate up
and down regulation, respectively. The effects on model components influenced by levels of
An are indicated by blue arrows and bars while the effects dependent on Ab are denoted in
yellow. Similarly, the nitric oxide effect on lactate production is colored in green. And the
implicit action of phagocyte inflammation over the transformation of glycogen into glucose















































= kdnh(αxX + P )− g(Ab)µdD (14)
dCA
dt














































































(Yn + Yb)− µLL (19)
dNit
dt
= snit + knoX − µnitNit (20)
dLPS
dt
= slpsD + klps













= sg + µgly(1 +N)Gly − λan (c(Ab) + c(An))G− kglyG (22)
dGly
dt




















− µY Yn (25)
where
f (V ) =
1
1 + V 2
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Table 4: Healthy equilibrium state values for equations (12)-(25)
Variable Equilibrium Variable Equilibrium
Value Value
P 0 L
















positive solution to Ax2 + Bx + C = 0 where
An 1 Yb A = −µy
B = 2λankAG− Ymax − µY Ymax
C = 2λankAGYmax
positive solution to Dx2 + Ex + F = 0 where
X 0 Yn D = −µy




Similar to the original model, the extended model also presents three biologically relevant
equilibrium points, healthy, aseptic, and septic. Sample trajectories of these states are shown
in Figures 18, 19, and 20. We present these trajectories in logarithmic time scale for better
visualization. These three trajectories were obtained with the same set of parameters and
initial conditions shown in Table 5, and only varying the pathogen growth rate kpg.
In the healthy state trajectory (Fig. 18), pathogens P enter the host and trigger an
immune response led by activated phagocytes. This response quickly resolves the infection
within the first 10 to 15 hours. During this time, anti-inflammatory mediators play a funda-
mental role in down-regulating inflammation at expenses of energy. There is a rise in tissue
damage that leads to accumulation of nitric oxide, lactate, nitrate, and LPS. However, a
proper balance of glucose provides enough ATP to sustain CA production as well as to main-
tain an adequate tissue healing. Just before pathogens are eliminated, phagocytes take a
second rebound. However, a proper down-regulation from the anti-inflammatory mediators,
controls such rebound and allows the trajectories to land back in the healthy state.
The aseptic trajectory (Fig. 19) shows a similar behavior for the beginning of the simu-
lation. However, this time pathogens replicate at a higher rate, and therefore need a much
faster immune response that quickly is out of control and the CA can not sustain for too
long. This uncontrolled inflammation leads to a rapid increase in nitric oxide, tissue damage,
nitrate and lactate. Finally, energy is consumed in an attempt to fight the over inflammatory
response, leading to a drop in the glucose and glycogen levels.
In the septic trajectory (Fig. 20), the pathogen rate is so fast that the immune response
is unable to mitigate their reproduction. At about 20 hours the immune system cannot
hold the infection anymore and pathogens start to take over the host. As an attempt to
fight this rapid infection, energy reserves are consumed and are not enough to neither fuel
anti-inflammatory mediators nor provide an adequate tissue healing response. This leads to
elevated values of nitric oxide, which trigger higher tissue damage and LPS.
Unlike the previous model presented in Chapter 2, ATP can now attain values higher
than 1. This happens when there is a glucose uptake or high energy response. However, the
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ATP healthy steady state value is still 1.
3.5 Discussion
We developed and extended model that includes the dynamics of the acute immune response
along with the energy requirements that are needed when fighting an infection. This model
builds on the previous work done in [59] and presented in Chapter 2 of this thesis. A data-
oriented approach was followed in the development of the model, on which we included
and modified new equations to describe the observed animal data. We provide a thorough
description of the model equations and parameters and illustrate the transient dynamics of
three biologically significant equilibrium points: healthy, aseptic, and septic.
In equations (10) and (11), we showed that the parameters kb and kn are fixed but
dependent on other model parameters. In particular, these two parameters are µA-dependent.
Therefore, using the notation kb = k̂bµA and kn = µAk̂n, where
k̂b =
(Ymax + Yb)




sg(Ymax + Yn) + 15βεnYmaxYn
(27)











































Unlike in the reduced model presented in Chapter 2, µA is involved not only in the
depletion rate of ATP but also in its own production rate. This suggests that parameter
µA can be understood as the energy rate constant. This equivalent way of writing the ATP
equations will be convenient later on in Chapter 5 when we discuss the role of important
parameters to predict patient outcome.
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The new extended model improves our previous model in that it includes the dynamics
of commonly measured variables in the ICU and therefore can eventually be calibrated with
human data. However, with a more realistic model comes the downside of having more
unknown parameters and complicated non-linearities that can potentially make parameter
estimation challenging. When fitting a complex non-linear dynamical system with human
data, issues like unidentifiable parameters and computational limitations can present barriers
to extract useful information from this models.
Nitric oxide has also been found to have protective roles in response to inflammatory
estimuli, including preservation of blood flow and prevention of platelet adhesion [53]. Future
extensions of this model include incorporating such protective roles of nitric oxide. This
model can also be used to form compartmental models for the study of multiple organ
dysfunction syndrome (MODS) by including the dynamics of certain organs like the liver
and lungs. Model and parameter dimensionality reduction are also part of possible future
directions.
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Figure 18: Sample model trajectories for the healthy state. Parameter values are given in
Table 5. Initial conditions are computed as in Table 4, with the exception of initial pathogen
load which is P (0) = 1.
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Figure 19: Sample model trajectories for the aseptic state. All parameter values are given
in Table 5 with the exception of kpg = 0.13907. Initial conditions are computed as in Table
4, with the exception of initial pathogen load which is P (0) = 1.
55
Figure 20: Sample model trajectories for the septic state. All parameter values are given in
Table 5 with the exception of kpg = 0.17615. Initial conditions are computed as in Table 4,
with the exception of initial pathogen load which is P (0) = 1.
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Table 5: Parameter values for the health sample trajectory
Parameter Value Description
kpg 0.1298 Pathogen growth rate
P∞ 20× 106/cc Carrying capacity for pathogen
kpm 0.000148 Rate parameter for the elimination of pathogens by the non-specific local response
kns 0.59934 Weighting of the energy-dependent component of non-specific pathogen elimination
µm 0.0044093/h Half-activation parameter for the non-specific local response
kmp 0.0001478 Saturation rate parameter for the non-specific local response
kpn 9.1058 Phagocytosis rate
C∗ 2.5114 Saturation parameter for effects of anti-inflammatory mediators
kps 0.34996 Phagocytosis saturation constant
snr 82.137 Production rate for activated phagocytes
knn 0.00088 Weight of contribution to activation of resting phagocytes
by previously activated phagocytes and their cytokines
knp 0.014887 Weight of contribution to activation of resting phagocytes by LPS
knd 0.00068064 Weight of contribution to activation of resting phagocytes by tissue damage
µnr 4.2731/h Decay rate of resting phagocytes
µn 0.94573/h Decay rate of activated phagocytes
kde 15.119 Pathogen degradation enhancement constant
kdn 0.016343 Maximum rate of damage produced by activated phagocytes
αx 1.2639 Weight of contribution of creation of tissue damage by nitric oxide
xdn 0.41101 Determines levels of pathogens and nitric oxide needed to bring damage
production up to half its maximum
µd 0.026832/h Rate of tissue healing
sc 2.1859 Source of anti-inflammatory mediators
kcn 24.893 Maximum production rate of anti-inflammatory mediators
kcnd 907.29 Effectiveness of damaged tissue relative to activated phagocytes in
inducing production of anti-inflammatory mediators
µcq 0.13048 Determines the levels of activated phagocytes and damage that are needed to bring
rate of anti-inflammatory mediator production to half its maximum
µc 9.9179/h Decay rate of anti-inflammatory mediators
µA 24.743 Energy rate constant
cg 2.8237 Half-saturation energy level for the driving of various processes
kb 0.14951 Scaling parameter to balance units of glucose and pyruvate in the Ab production process
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Table 6: Parameter values for the health sample trajectory continued
Parameter Value Description
β 0.74611 Fraction of pyruvate that is converted into ATP during aerobic respiration
X∗ 0.43276 Half saturation level of NO
Ymax 22.326 Maximum saturation value for pyruvate
λan fixed at 100 ATP production during anaerobic glycolysis is about 100
times faster than during phosphorylation
kA 0.0043282 Homeostatic value of modulator function c(Ax), i.e when Ax = 1
k1 0.91496 Phenomenological energy production parameter
k2 0.083895 Phenomenological energy production parameter
c1 169.98 Energy consumption rate of Φ1
c2 206.03 Energy consumption rate of Φ2
c3 2.5215 Energy consumption rate of Φ3
c4 1366.2 Energy consumption rate of Φ4
c5 0.29397 Energy consumption rate of Φ5
c6 0.023474 Energy consumption rate of Φ6
kn 0.22686 Scaling parameter to balance units of glucose and pyruvate in the An production process
εn 0.0018957 Denotes lower production of An through the anaerobic pathway
knon 99.788 Rate of NO release due to presence of pro-inflammatory cytokines
knod 24504 Rate of NO release due to tissue damage
µno 18174 Natural depletion rate of NO
λL 0.2081 Production rate of lactate
µL 0.086296 Decay rate of lactate
snit 28.159 Source of nitrate
kno 355.66 Rate at which NO is converted into nitrate
µnit 1.7728 Decay rate of nitrate
slps 1046.1 Source of LPS
klps 23206 Rate at which LPS is released after pathogen membrane breaking by immune cells
µlps 3.0929 Decay rate of LPS
sg 108.96 Source of glucose
µgly 1.2347 Rate at which glycogen is converted into glucose
kgly 3.1658 Rate at which glucose is converted into glycogen
µY 15.915 Decay rate of pyruvate
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4.0 Parameter estimation on data-driven model
4.1 Introduction
Once a mathematical model provides qualitative features that are consistent to the known
biology of the problem of interest, we proceed to a second stage known as parameter estima-
tion. There are some standard techniques that are commonly used when modeling complex
biological processes. In this chapter we begin by utilizing the so called ordinary least squares
method to obtain a nominal set of parameters that better explains our data. We present
a brief introduction to the method and then present the results and conclusions. We then
present an introduction to Bayesian parameter estimation and use it to quantify uncertainty
on the model parameters. More specifically, we use an delayed rejection adaptive metropolis
algorithm and available data to construct a distribution of parameters that resembles patient
heterogeneity. The main goal in this chapter is to find distributions for model parameters
that can be used to predict patient outcome with certain probability.
4.2 Ordinary least squares (OLS)
The standard ordinary least squares (OLS) formulation involves a mathematical model and
a statistical model [4] [11]. The mathematical model can be written as:
dx
dt
= g(t, x(t, θ), θ) (30)
where x(t, θ) ∈ Rm corresponds to the parameter state variable vector at time t and θ ∈ Rp
denotes the parameter vector and p the number of parameters.
We denote the model output by f(ti, θ0) which is a functional of the state variable x(t, θ).
That is f(ti, θ0) ∈ F (x(t, θ)) and θ0 is the true parameter vector. In our case, the statistical
model for the observation process will be given by
ln(Yi) = ln (f(ti, θ0)) + Ei (31)
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where Yi is a vector of random variables with realizations yi. We assume the errors Ei are in-
dependent and identically log-normally distributed random variables, that is cov (Ei,Ej) = 0
whenever i 6= j. We assume different observation coordinates fi may have different vari-
ances σ2i associated with different coordinates of the errors Ei. Then Ei is an m-dimensional
random vector, [4]. We also assume E[Ei] = 0, and that var(Ei) = V0 = diag(σ20,1, · · · , σ20,m).
Typically the method of ordinary least squares consists in minimizing the objective func-
tion consisting on the sum of square differences between data and the model. The objective
function can however be modified to normalize residuals and also include heuristic terms




wi [ln(Yi)− ln (f(ti, θ))]2 +H (32)
where the minimum is taken over the set of parameter vectors θ constrained by a pre-specified
feasible region denoted Θ. The minimizer is a random variable, called the estimator θOLS




wi [ln(Yi)− ln (f(ti, θ))]2 +H (33)
The theoretical quantity θ0 is in general unknown. In practice, one has only the data
associated with a single realization yi of the observation process Yi for i = 1, 2, · · · , n and




wi [ln(yi)− ln (f(ti, θ))]2 +H (34)
In our case, in order to use fit the model with the data, we first define
Elas(ti, θ) = N(ti, θ) + elasb (35)
where elasb is a shifting parameter that scales the N trajectory to fit the elastase data.
Parameter elasb will from now on be part of the unknown parameter set. Therefore, from
now on and for the rest of this chapter, for fitting purposes we will use equation (35) instead
of equation (13). Further, we define
f(ti, θ) = [Elas(ti, θ), L(ti, θ), Nit(ti, θ), LPS(ti, θ), G(ti, θ)]
T (36)
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and then ln (f(ti, θ)) in equation (34) indicates taking the logarithm entrywise.
As all subjects in the experiment were given the same amount of initial bacterial load,
we assume all survivors will have similar response against the infection. Therefore, we use
the OLS method described here to estimate a nominal set of parameters for the average data
trajectory obtained with the non-treated survivors S89, S90, S100, and S101.
In order to use the formulation of the OLS described above, we define an appropriate
objective function that includes the fact that measurements are in logarithmic scale, that it
normalizes the distance between data and the model, and that ensures we obtain a set of
parameters whose outcome is a survivor trajectory, by including heuristic terms. Therefore,
we are interested in finding
θ̂OLS = argminθ∈ΘG(t, θ) (37)










































Here, θ = (θ1, · · · , θM) is the vector of unknown model parameters to be determined
and the data points are collected at times t = t1, · · · , t11, as described in Section 3.2. This
function consists of the normalized difference squared between the natural logarithm of the
observed data and the natural logarithm of the model. In particular, we use weighted
Heaviside functions as heuristics to impose certain conditions we want our output trajectory
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to satisfy. We note that in the data, at the first and last time points, t0 and t11, LPS was
recorded to be exactly 3.5 across all individuals in the placebo group. This suggests that
3.5 corresponds to the lowest level of detection observed in LPS instead of being the actual
recorded value. We introduce the terms ω1H(LPSmodel(t0)− 3.5) and ω2H(LPSmodel(t11)−
3.5). In these terms, H(x−a) is the Heaviside function that equals 0 when x < a and equals
1 when x− a > 0. Overall, the idea is to force the algorithm to search for parameter values
that satisfy that LPSmodel(tj) < 3.5 for j = 0, 11.
Similarly, in order to obtain an elastase trajectory that also goes below the level of
detection of 0.11 at time t11, we impose the condition ω3H(Elasmodel(t11)−0.11). Moreover,
the terms ω4H(Dmodel(t11) − 0.0001) and ω5H(Pmodel(t11) − 0.0001) force the algorithm to
search in the parameter space for values for which Dmodel(t11) and Pmodel(t11) lie below 0.0001,
which we use as threshold to define a healthy trajectory. The term ω6H(max(CA) − 2C∗),
guarantees the maximum value achieved by the model variable CA does not passes 2 times
its half saturation given by C∗. The parameters ωi are penalty weights, and depending on
how much weight one wants to put on each penalty condition, ωi can be modified. However,
we used ωi = 100 for all i = 1, · · · , 6, as we wanted to have equal weight.
It is important to note that every term in the sum of squares is weighted by a term of the
form log(VSD(ti)) where VSD(ti) corresponds to the standard deviation of the measurement V
at time ti. Also, because subjects were fed during times t7, t8, and t9, we observed a glucose
increment that is not part of the inflammatory response we are interested on. Therefore, we
will not be considering these time points in glucose trajectory for data fitting.
We used the patternsearch algorithm from Matlab R2018b to minimize the objective
function G(t, θ) and to speed up the process of solving the system of differential equations
and calculate Ymodel, we used CVODE as provided in SUNDIALS, [40]. The values of the
parameters obtained in the OLS are given in Table 7. All but six parameters were left free.
We assume pathogen load has a maximum carrying capacity of P∞ = 20×106/cc, λan = 100
corresponds to the speed at which anaerobic respiration occurs (100 times faster than aerobic
respiration). We estimated C∗ = 2, and the maximum production rate of anti-inflammatory
mediators at kcn = 49.483. Lastly, kb and kn are fixed but depend on other parameters.
They can be computed as shown in equations (10) and (11).
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The resulting best fit trajectory is depicted in Fig. 21 in logarithmic scale whereas Fig.
22 shows the same plot in linear scale up to 150 hours. Similarly, the corresponding model
trajectories in logarithmic scale are shown in Fig. 23 and in linear scale for the first 50 hours
in Fig. 24. We observe that within the first hour, the presence of pathogens activate an
inflammatory response which is responsible for the rise in nitric oxide and consequently in
tissue damage and lactate. As pathogens are eliminated by neutrophils and other immune
cells, LPS builds up contributing also to the increase in tissue damage. In an attempt to
control the inflammatory response, anti-inflammatory mediators CA also kick in during the
first hour after infection. In the urge of a quick response for the ATP demand to fuel both the
inflammatory and anti-inflammatory cascade, glycogen is quickly transformed into glucose.
During the next few hours pathogens are gradually eliminated until at about t = 10 hours
they are no longer in the system. Because no more pathogens are around and an adequate
amount of anti-inflammatory mediators, N starts decreasing and inflammation seems to be
under control. However, because at 10 hours CA is lowering down and tissue damage is
still building up, due to the still high values of nitric oxide and LPS, neutrophils have a
rebound. Such rebound activates again the CA production fueled by ATP in an effort to
control inflammation and tissue healing. After the first 10 hours, tissue starts to recover
from damage, LPS continues decreasing and CA finally down-regulates inflammation until
N decays to rest on the healthy equilibrium at the end of the simulation.
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Table 7: Best fit parameter values and initial conditions for average of the survivors
Parameter Value Parameter Value Parameter Value
kpg 0.12388 sc 1.4416 c6 0.01396
P∞ fixed at 20 kcn fixed at 49.483 kn fixed at 0.173
kpm 0.0002 kcnd 767.46 εn 0.00183
kns 0.37134 µcq 0.071231 knon 91.07
µm 0.00298 µc 5.8034 knod 14162
kmp 0.00075 µA 14.638 µno 10739
kpn 7.1696 cg 1.8958 λL 0.16851
C∗ fixed at 2 kb fixed at 0.1025 µL 0.0711
kps 0.29301 β 0.91389 snit 26.363
snr 53.567 X
∗ 0.24701 kno 317.8
knn 0.00058 Ymax 12.016 µnit 1.6219
knp 0.00818 λan fixed at 100 slps 1158.7
knd 0.00039 kA 0.0038 klps 27240
µnr 3.0008 k1 0.8257 µlps 2.6421
µn 0.59336 k2 0.05597 sg 84.131
kde 11.762 c1 103.48 µgly 0.80734
kdn 0.02982 c2 106.95 kgly 1.7424
αx 1.2697 c3 2.0714 µY 12.039
xdn 0.2617 c4 2055.7 elasb 0.51786
µd 0.04848 c5 0.15979 P (0) 1
N(0) 0 D(0) 0 CA(0) 0.24841
Ab(0) 1 An(0) 1 X(0) 0
L(0) 2.7794 Nit(0) 16.254 LPS(0) 0
G(0) 110.66 Gly(0) 238.83 Yb(0) 6.6332
Yn(0) 6.9875
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Figure 21: Best fit for the observable trajectories in average of the survivors obtained with
OLS with logarithmic time scale. Parameter values and initial conditions are given in Table
7.
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Figure 22: Best fit for the observable trajectories in average of the survivors obtained with
OLS in linear scale. Parameter values and initial conditions are given in Table 7.
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Figure 23: Model trajectories obtained with best fit for the average of the survivors with
logarithmic time scale. Values for parameters and initial conditions are given in Table 7.
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Figure 24: Model trajectories obtained with best fit for the average of the survivors in linear
scale. Values for parameters and initial conditions are given in Table 7.
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4.3 Bayesian inference for parameter estimation
In the Bayesian inference setting it is standard to work with the statistical model
Yi = f(ti,Θ) + Ei ; i = 1, · · · , n (39)
Here f(ti,Θ) represents the parameter dependent model response, and Yi, Ei, and Θ are
assumed to be random variables representing measurements, measurement errors, and pa-
rameters, respectively [68].
We assume the random variable of unknown vectors Θ has realizations θ with correspond-
ing distribution π(θ), also known as the prior distribution. The prior distribution contains
any prior information we may know about the parameter vector θ. If information of the
parameter of interest can be found in the literature or can be estimated experimentally, we
may assume its prior distribution is given by a Gaussian distribution with certain mean and
standard deviation. However, if no previous information is known about this parameter, it
is preferred to use a non-informative prior. In biological models for instance, it is common
to work with positive parameters and usually no other information is known. If this is the
case, one can use a non-informative prior defined as an improper uniform density given by
π(θ) = χ(0,∞)(θ), [68].
The posterior distribution P (θ|y), which is our quantity of interest, corresponds to the
probability distribution of the parameter θ given the observed data y. Determining the
posterior distribution using prior information given by the observed data can be done by
making use of the so called Bayes formula:
P (θ|y) = P (y|θ)π(θ)
P (θ)
(40)
Bayes formula provides a relation between the posterior distribution, the prior distribution
and the likelihood function. The likelihood function P (y|θ), corresponds to the probability
of obtaining the data y given the parameter value θ. The term P (θ) is the probability
distribution of the observed data. This last term is a normalization factor to ensure the




P (y|θ) π(θ)dθ (41)
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where N is the number of unknown parameter values.
As shown in [68], if we assume that the measurement errors Ei are independent and
identically distributed (iid) and that they are given by a normal distribution centered at 0
and with fixed standard deviation σ2, the likelihood function is








[yi − fi(θ)]2 is the sum of squares error.
Evaluating the posterior relation given in (40) is usually complicated or even impossible,
especially for high dimensional parameter spaces as it involves the evaluation of (41). As
an alternative approach, we can construct Markov chains, using Markov Chain Monte Carlo
(MCMC) techniques, whose stationary distributions is the desired posterior distribution
P (θ|y). Evaluating realizations of the chain allow us to sample the posterior to obtain a
density for the parameter values based on the observed measurements, [68].
In simple words, the MCMC sampling algorithms generate a chain of random variables
that satisfy the Markov property that Xk depends only on Xk−1, where the state space
X is the space of all possible parameter values. If we suppose a current parameter vector
θk−1 is obtained from the chain realization Xk−1 = θ
k−1, a new candidate θ∗ is proposed,




. We then accept




, that is, we let Xk = θ
∗ with probability α and let Xk =
θk−1 otherwise. In the Metropolis algorithm we consider the proposal distribution to be









An important feature of MCMC sampling that makes it an useful technique in Bayesian
inference is that we avoid having to compute the term (41), as during the sampling process,





























where in the second equality we used the symmetry of the proposal distribution, in the third









as the ratio of posterior densities. This ratio is then used to compute the probability α
mentioned above, as we will discuss in the following section.
4.3.1 Random walk Metropolis algorithm with non-informative prior
In this section we describe the Metropolis algorithm when no prior information is used. Here,


















where V is the covariance matrix of Θ and D is a diagonal matrix whose elements represent
the scale corresponding to each parameter value. These choices for the proposal are motivated
to scale the variability of each parameter component [68].
The algorithm to construct a chain X of length M is as follows:
1. We start by choosing an initial parameter θ0 such that P (θ0|y) > 0
2. For k = 1, · · · ,M we propose the candidate θ∗ = θk−1 +Rz, where z ∼ N(0, 1) and R is
the Cholesky decomposition of V .








∗ ,with probability α = min(1, r),
θk−1 , otherwise.
(47)
The step 2 of the algorithm corresponds to the Markov step, as θk depends only on
the previous (k − 1)-th iteration. The construction of θ∗ ensures that θ∗ ∼ N(θk−1, V ) or
θ∗ ∼ N(θk−1, D) [68].





















which in turn implies that
SSθ∗ < SSθk−1 and then we accept θ
∗ with probability 1, as θ∗ provides a smaller sum of
squares. On the other hand, if r < 1, we accept θ∗ with probability α = r. Finally, we note
that when the prior distribution is non-symmetric, we obtained a generalized version of the
Metropolis algorithm called the Metropolis-Hastings algorithm.






















yi − f(ti, θ̂OLS)
]2
(50)
where n is the number of data points, N is the number of unknown parameters, θ̂OLS is the
parameter vector obtained in the OLS that corresponds to the best fit trajectory found in
Section 4.2, and χik(θ) =
∂f(ti, θ)
∂θk
is the sensitivity matrix.
Finally, if prior information is known about the parameters, step 2 is then adapted to
include this prior. For example, if parameters are known to be normally distributed with
mean µ and standard deviation σ, we propose candidates θ∗ = z where z ∼ N(µ, σ2), [74].
The chain X consists of all accepted vector parameters θk. To allow the chain to reach
stationarity and therefore converge to the posterior distribution it is required to disregard
the first part of the chain that may have transition behavior across different local minima.
This initial period is called the burn-in period. The exact length of the burn-in period is
an entire topic of discussion. However, a standard technique is to monitor the paths of the
chain associated to each parameter, [68].
4.3.2 Delayed rejection adaptive Metropolis algorithm (DRAM)
The DRAM algorithm was introduced by Hario et. al [37]. A simplified description of the
algorithm and implementation can be found in [68]. Here we summarize the most important
remarks addressed in [68].
Adaptive algorithms, including the DRAM algorithm, use information learned about the
posterior distribution as the candidates parameters are accepted. As the name suggests, the
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DRAM algorithm consists of two stages, an adaptive metropolis (AM) part and a delayed
rejection (DR) part. The AM uses information learned about the posterior through the
accepted chain candidates to update the proposal via the chain covariance matrix. DR
alters the proposal function to improve mixing.
The AM part of the algorithm starts with an initial stage of length k0 where adaptation
has not begun. In this stage the chain values θ0, θ1, · · · , θk−1 are calculated using the initial
covariance matrix V0 = V where V is given as in the Metropolis algorithm. Once this initial
stage ends, adaptation begins by updating the covariance matrix at the k-step by
Vk = sNcov
(
θ0, θ1, · · · , θk−1
)
+ εIN (51)
where sN is a design parameter that depends on the number of unknown parameters N ,
commonly chosen as sN = 2.38
2/N , according to [37]. It is important to note that adaptive
algorithms are no longer Markovian processes, as they use information about more than one
previous state of the chain. The addition of the term εIN allows Vk to be positive definite,
where we take ε ≥ 0 and IN is the N ×N identity matrix.
As we discussed above, in the standard Metropolis algorithm the candidates are either
accepted with probability α(θ∗|θk) or rejected, in which case the previous candidate θk−1 is
retained. The delayed rejection algorithm provides a second alternative candidate θ∗2 which
is chosen instead of rejecting and retaining the previous candidate.






























indicates that we are proposing θ∗2 having started at θk−1 and rejected θ∗. Here Vk is as in
(51) and γ22 < 1 to ensure the second proposal is narrower than the first one.
The combination of AM and DR provides two different mechanisms that complement
each other to modify the proposal. With the chain covariance matrix, AM updates the
73
proposal using information learned about the posterior through accepted chain candidates.
The DR improves mixing by modifying the proposal function in a predetermined manner.
Such modifications in the proposal are temporary and have the goal to stimulate mixing.
However, the AM produces permanent changes that reflect information learned about the
posterior, [68].
The Metropolis algorithm uses parameter scaling and variability in the proposal as seen
in equation (46). However, one of the advantages the DRAM algorithm offers is that it
provides a mechanism to incorporate information obtained during the run of the chain about
the posterior distribution [37], [68].
More details about the form of α2 can be found in [68]. The construction of a jth-stage
candidate, the acceptance condition, and more details about the DRAM algorithm can be
found in [37]. The MATLAB toolbox used to run our MCMC simulations in the following
sections can be found at the website https://mjlaine.github.io/mcmcstat/.
4.3.3 Space distribution of virtual subjects
In this section we describe the construction of an ensemble of virtual subjects using the
DRAM algorithm. We denote this distribution Xtot as it will be used to resemble the space
of all possible septic patients. Ideally this distribution will include patient heterogeneity
observed in real patients. As the DRAM algorithm is based on the Metropolis algorithm, we
need to define the sum of squares used in equation (48) to compute the ratio of likelihoods.











Here Npt is the number of time points for the corresponding subject that is being fitted.
When fitting survivors, Npt = 11, but when fitting non-survivors Npt varies depending of the
time of death of the corresponding subject. That is, each sum of squares is normalized by
the number of observed data points. Because subjects were fed during times t7, t8, and t9,
we will not consider these data points when fitting the glucose trajectory. Also, instead of
imposing any heuristic on the first LPS data point, we decided to not include it in the fitting
and allow the algorithm to freely choose at this time point.
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where the last term is a Heaviside function that is used as a heuristic to force the algorithm
to search for parameters in the non-survival regime. Also, Ngp corresponds to the number of
glucose points that are not being fitted. Because non-survivors data may or may not include
t7, t8, and t9, then Ngp can be either 0,1,2, or 3.





































where unlike in the OLS step, we are normalizing by the constant ln(VSD) which corresponds
to the average of the standard deviation for measurement V at all time points. Finally, for
simplicity, when computing r(θ∗|θk−1) in equation (48), we use σ2 = 1.
To construct the total distribution Xtot we proceed as follows:
1. For i = 1, · · · , 16
a. Use DRAM to generate the chain Xi corresponding to the ith-subject.
b. Take a random subsample of Xi called X̂i.





In step 1.a we use the individual data for the i-th subject to fit the model using DRAM
and thus obtain an ensemble Xi. Each ensemble Xi consists of M = 200000 parameter
vectors of size Np × 1. Here, Np = 55 is the number of free parameters to be estimated
and M is the length of the chain, i.e. the number of virtual patients in the ensemble. We
repeat this process for each subject to obtain 16 ensembles of size M ×Np. The number M
corresponding to the length of the chain was arbitrarily chosen and it can be increased or
decreased. Keeping this number large however, will help to obtain convergence of the chain.
In order to remove the initial transition of the chain to achieve a minima, a burn-in of length
50000 iterations was thrown away for each chain.
To illustrate this process, in Fig. 25 we present the marginal path trajectories obtained
when fitting subject S89 with DRAM. The chain path does not stagnate suggesting the
proposal is neither too narrow nor too wide. This situation is ideal as it suggests there was
a rich chain mixing and substantial exploration of the parameter space. The stationarity of
the chains indicates that they have burned-in and are sampling from the posterior density.
As depicted in the figure, the length of each path trajectory is 2 × 104 where the burn-in
portion of the chain has already been discarded.
Along with the chain, we compute marginal densities for each of the individual fits. Fig.
26 depicts the marginals obtained when fitting S89 with DRAM. More localized marginals
provide a sense of the likelihood of each parameter. For example, for subject S89, it is more
likely to observe β values between 0.8 and 0.94. Whereas for µA it is more likely to attain
values between 21.2 and 29.08. On the other hand, flatter marginal distributions suggest
that the corresponding parameters are not uniquely identifiable.
Each chain also allows us to quantify uncertainty on the observable and model trajecto-
ries. This uncertainty can be observed for instance in Fig. 27, which shows the envelopes of
the observed variables for the four survivor subjects S89, S90, S100, and S101. Similarly, in
Fig. 28 we also present the envelopes for four of the non-survivors; NS73, NS74, NS88, and
NS98. We also present the envelopes of model trajectories for subjects S89 in Fig. 29 and
NS73 in Fig. 30.
In step 1b, from each of the 16 distributions Xi, we select random samples of size M/16 =
12500 to obtain subsample distributions X̂i of the same size. In step 2, we collect all these
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subsamples and combine them to form the total space distribution Xtot. In other words,
Xtot is a collection of 16 distributions, where each distribution was created by sampling
parameters that fit each individual subject with certain probability. Therefore the ensemble
in Xi is a set of parameters that resembles the uncertainty when collecting the data of the i-
th subject. Moreover, this construction ensures that the total space distribution will consist
of a chain of parameter vectors θ1, θ2, · · · , θM such that when θi is evaluated into the model
equations (12) - (25) its outcome results in either a survivor or a non-survivor trajectory.
The marginal densities of the total distribution Xtot are shown in Fig. 31. Because this
is a combination of the marginals of all 16 subjects we obtain wider and flatter densities than
in the individual case and no many conclusions can me made at first sight. However, this
gives us a sense of how parameters are distributed within their initial domain in the entire
virtual population and in some cases, like is the case with kpg, β, kA, etc, we can estimate
their value based with certain likelihood.
Although no prior information is being used for the individual fits in step 1a, the DRAM
algorithm requires bounds to define the domain of each of the sampling parameters. To define
this domain, we use the parameter vector θ̂OLS found in Section 4.2, which corresponds to
the best fit to the trajectory of the average of the survivors. Assuming patients behave more







determine the parameter bounds to be used in the DRAM algorithm.
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Figure 25: Parameter chain paths obtained with DRAM when fitting S89. The y-axes
contain the parameter domains and in the x-axes the number of elements in the chain.
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Figure 26: Marginal parameter densities obtained with DRAM when fitting S89. The
parameter domains are shown in the x-axes whereas parameter frequency are shown on the
y-axes.
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(a) (b) (c) (d)
Figure 27: Envelopes of observed trajectories for subjects (a) S89, (b) S90, (c) S100, and (d)
S101 obtained with DRAM. The solid blue line corresponds to the median of the sampled
trajectories and the shaded gray regions enclose the 5% − 95% confidence intervals. The
black dots correspond to the data and the bars the average of the standard deviation of the
treated non-survivors.
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(a) (b) (c) (d)
Figure 28: Envelopes of observed trajectories for subjects (a) NS73, (b) NS74, (c) NS88,
and (d) NS98 obtained with DRAM. The solid blue line corresponds to the median of the
sampled trajectories and the shaded gray regions enclose the 5%− 95% confidence intervals.
The black dots correspond to the data and the bars the average of the standard deviation of
the treated non-survivors. 81
Figure 29: Predicted intervals of model trajectories obtained with best fit for subject S89.
The solid blue line corresponds to the median of the sampled trajectories and the shaded
gray region bounded by the black dashed lines enclose the 5%− 95% confidence interval.
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Figure 30: Predicted intervals of model trajectories obtained with best fit for subject NS73.
The solid blue line corresponds to the median of the sampled trajectories and the shaded
gray region bounded by the black dashed lines enclose the 5%− 95% confidence interval.
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Figure 31: Marginal parameter densities of total distribution Xtot. The y-axes contain
parameter frequencies and x-axes parameter domains.
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4.3.4 Validation of the total distribution
In this section, we use the Random Walk Metropolis Algorithm described in Section 4.3.1,
but this time with an informative prior. In particular, proposed candidates will be randomly
chosen from the total distribution Xtot rather than with the process described in step 2 in
Section 4.3.1. However, candidates θ∗ at the k−th stage will still be accepted with probability
α or taken as θk−1 if rejected.
We use the Metropolis algorithm with informative prior to fit each of the 16 subjects
data in the placebo group, to determine whether the model can provide results that are
consistent with the data. For instance, if we plug the data of the survivor subject S89
into our Metropolis algorithm with informative prior, we expect to obtain a high survival
probability. Similarly, if we plug the data of a non-survivor subject like NS66, we expect the
model to predict high mortality probability.
Table 8: Metropolis with informative prior: individual fits for non-treated subjects
Subject Prob. Surv. Prob Non-Surv Subject Prob. Surv. Prob Non-Surv
NS66 2.46% 97.54% S89 100% 0%
NS67 36.58% 63.42% S90 100% 0%
NS69 0.08% 99.2% NS92 0.5% 99.5%
NS73 0.72% 99.28% NS97 3.92% 96.08%
NS74 58.8% 41.2% NS98 49.78% 50.22%
NS76 2.04% 97.96% S100 100% 0%
NS80 6.76% 93.24% S101 100% 0%
NS88 56.06% 43.94% NS104 17.32% 82.68%
On Table 8, we present a summary of the results of what the model predicts when
implementing Metropolis with Xtot as informative prior to fit each of the 16 sets of data
from the non-treated cohort. For the most part, the model is able to predict patient outcome
for the available data, with the exception of the non-survivor subjects NS67, NS74, NS88,
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and NS98. There are several reasons of why the algorithm is not providing an accurate
prediction for these cases. According to Fig. 32a, when fitting subject NS67, the algorithm
chooses parameters from several distributions but mostly from the distributions obtained
with NS67 and S100, with a slightly higher amount from NS67. This suggests that the data
sets of these two subjects are relatively similar and therefore high survival probability is
estimated for subject NS67, despite the fact that NS67 is a non-survivor subject. The same
behavior is observed when fitting the data of subject NS98 seen in Fig. 32d, although this
time the algorithm is also selecting parameters from the distributions of S90, S100, and S101,
suggesting again that NS98 and these three survivors have similar data trajectories. A similar
situation is observed when fitting NS74 and NS88, as depicted in Fig. 32b and Fig. 32c,
respectively. Here we note that Metropolis experiences difficulties and selects considerably
more trajectories from S100, resulting in high survival probability contradicting the fact that
these two data set trajectories are of two non-survivor subjects.
Finally, these four subjects survived at least for 35 hours and therefore the model might
be biased towards survival because of the length of the data. Based on this last observation,
we study the case where we consider only the first 5 and 6 time points on each of these
subjects. As shown in Table 9, reducing the number of time points results in more accurate
predictions from our model. This suggest that the proper recording of measurements during
the first 11 and 23 hours is crucial to predict patient outcome.
In Fig. 33 we observe the evolution of the algorithm when NS88 is fitted with 5, 6, and
9 data points. We note that in the fewer data point cases the algorithm picks parameters
mostly from the non-survivor distributions rather than the survivor distributions leading to
a more accurate prediction.
The algorithm performs remarkably well when predicting survival, as it predicts with
100% probability that subjects S89, S90, S100, and S101 are survivors. However, we are
interested to know whether our model can predict survival at earlier times. In particular, we
note that when using only 5 and 6 data points we still obtain positive results in 3 out of these
four subjects, as observed in Table 10. In Fig. 34 we note how when using all 11 data points
for S89, the algorithm selects parameter sets only from the four survivor distributions. But




Figure 32: Test results for NS67, NS74, NS88, NS98. The x-axes indicate the distributions
constructed with DRAM of the 16 non-treated subjects. The y-axes contain the percentage
of occurrence of each distribution.
sets from other distributions. However the algorithm soon recognizes this data is coming
from the S89 distribution, resulting in predicting high probability of survival in both cases.
Similar behavior is observed in S90 and S101.
In the case of S100 with 5 time points, the model predicts only 41.84% of survival
probability and with 6 time points it improves to 59.10%. This suggest that for the first
11 hours, subject S100 was not doing well, but later in the experiment its health improved.
The fact that when using the first 5 time points S100 has a relatively high probability of not
surviving of 58.16%, is also consistent with what we observed in Fig. 32, where the model
seems to find similarities between some non-survival trajectories and S100.
In Fig. 35 we present envelopes of the observable variables along with data when fitting
S89 with 5, 6 and 11 time points. As expected, the uncertainty would be larger when fitting
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Table 9: Metropolis with informative prior: individual fits on non-survivors
non-treated with 5 and 6 data points
5 time points 6 time points
Subject Prob. Surv. Prob Non-Surv Prob. Surv. Prob Non-Surv
NS67 9.7% 90.3% 11.46% 88.54%
NS74 26.76% 73.24% 24.69% 73.31%
NS88 26.74% 73.26% 19.52% 80.48%
NS98 28.33% 71.67% 13.74% 86.26%
less data points than when fitting all 11 data points. However the median trajectory does
not vary much across the three cases. The data points that were excluded in each case are
colored in red and the first data point at t = 0 hours is not shown in the envelopes as time is
in logarithmic scale. Similarly, the envelopes of NS88 for 5, 6, and 9 time points are shown
in Fig. 36, where we observe that including all data points force trajectories, to level down




Figure 33: Test results for NS88 with (a) 5 time points, (b) 6 time points, and (c) 9 time
points. The x-axes indicate the distributions constructed with DRAM of the 16 non-treated
subjects. The y-axes contain the percentage of occurrence of each distribution.
Table 10: Metropolis with informative prior: individual fits on survivors
non-treated with 5 and 6 data points
5 time points 6 time points
Subject Prob. Surv. Prob Non-Surv Prob. Surv. Prob Non-Surv
S89 59.18% 40.82% 90.50% 9.50%
S90 60.84% 39.16% 75.20% 24.80%
S100 41.84% 58.16% 59.10% 40.90%




Figure 34: Test results for S89 with (a) 5 time points, (b) 6 time points, and (c) 11 time
points. The x-axes indicate the distributions constructed with DRAM of the 16 non-treated
subjects. The y-axes contain the percentage of occurrence of each distribution.
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(a) (b) (c)
Figure 35: Envelopes for S89 with Metropolis with informative prior using (a) 5 time points,
(b) 6 time points, and (c) and 11 time points.
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(a) (b) (c)
Figure 36: Envelopes for NS88 with Metropolis with informative prior using (a) 5 time
points, (b) 6 time points, and (c) 9 time points.
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4.4 Discussion
This chapter constitutes an inverse problem on which the goal was to extract information
from data to estimate model parameters. Initially, we used an ordinary least squares like
approach to find parameter estimates for the average of the 4 survivors observed in the
animal study described in Section 3.2. This is based on the assumption that survivors have
a similar immune response to overcome the infection. Similarly, we assumed non-survivors
immune response is a deviation from a survivor response.
Using the first parameter estimates for the average of the survivors, we then used a
Bayesian approach to construct a distribution of parameters called Xtot, which reflects the
uncertainty observed in a population of septic patients. More specifically, we used a sampling
algorithm called DRAM, to first find parameter distributions that quantify the uncertainty
observed in the measurements collected for each of the 16 subjects in the animal study. Com-
bining the uncertainties observed in the entire study, we constructed Xtot. We assumed that
Xtot contains enough variability to reflect the heterogeneity a physician may encounter in a
diverse population of septic patients. Next, we used Xtot as a prior distribution to validate
our model via a Metropolis algorithm and the observed data. As a result, we obtained mor-
tality probabilities, that for the most part, were consistent with the true outcome (survivor
or non-survivor) of the original data.
We showed that our model can be used to predict probability of mortality given new
potential data. The validation process presented in Section 4.3.4 shows that our model can
be used to find similarities between data trajectories and predict patient outcome. The
model has difficulties predicting outcome for non-survivor subjects who have relatively long
time series. However, our results suggest that with 5 and 6 time points it is more likely
to obtain a reasonably accurate probability of survival. For this reason, it is important to
collect data points during the first phase of infection, that is, within the first 11 to 23 hours
after pathogen invasion.
The methods presented in this chapter can be used as a tool to predict patient outcome
with certain probability given data measurements of the five observable variables used in
our model: elastase, lactate, glucose, LPS, and nitrate. However, caution must be used
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when interpreting the results as there are certain limitations. For instance, it is unlikely
that our total distribution Xtot encloses enough variability to reflect the dynamics of all
possible septic patients. Therefore, even if the probability of survival is high, patients health
may become compromised for a number of reasons, including preexisting conditions or other
biological processes that are not included in the scope of our model. Nevertheless, our
model can be used as a complementary tool to evaluate patient’s evolution of the infection
and help physicians to make more informed decisions. Even though our model is highly
complex and allows us to explore the dynamics of an acute immune response during sepsis,
the corresponding envelopes do not capture all data points. This is part of the challenges of
working with aggregated patient data and to deal with heterogeneity in a real population of
septic patients.
The large value estimates in parameters like µc, kcn, and sc, suggest a relatively rapid anti-
inflammatory response. One of the model limitations is that we do not capture heterogeneity
of different anti-inflammatory cytokines in the body. However, making this distinction would
increase the number of state variables and the number of unknown parameters.
Step 3 in the Metropolis algorithm involves the numerical solution of the model for suf-
ficient number of samples. This is a computational expensive process, especially when the
model consists of many state variables and high dimensional parameter spaces, which is our
case. To speed-up this process we use CVODE as provided through SUNDIALS [40] to solve
the system of differential equations. Although CVODE considerably reduces the computa-
tional time, it still may take several hours to complete one chain simulation. In order to
obtain chain convergence it is recommended make several simulations and therefore increase
the computational time. This complicates the use of our model to provide predictions in a
reasonable amount of time to treat real patients. Also, the price paid for using CVODE is
that for certain parameter choices, the solver does not integrate or even crashes. For those
parameters for which the CVODE solver does not perform well we use the stiff solver ode15s
in MATLAB 2020a. However, still for a small amount of cases ode15s may also have troubles
integrating. Because the number of times this happened was sufficiently low compared to
the number of total simulations, it does not affect the results.
Although DRAM improves the standard MCMC sampler, there are other available tools
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that can be also used to improve computational time and/or sampling selection. Valderrama-
Bahamóndez et. al [81] presented a comparison of the performance of different MCMC
techniques including Metropolis-Hastings, parallel tempering MCMC, adaptive MCMC, and
parallel adaptive MCMC. They found better results in parallel adaptive MCMC when used to
estimate parameters in five ODE models in Systems Biology. Most recently, Bianconi et. al
[7], presented an alternative Bayesian method called Conditional Robust Calibration (CRC)
and compared it with DRAM and other state of the art approaches such as Profile Likelihood
and Approximate Bayesian Computational Sequence Monte Carlo. They found a reduction
in computational cost and robust solutions when applying CRC to three biological models.
Lastly, improvements in efficiency can be achieved when evolution algorithms combined
with self-adaptive randomized sub-space sampling. This is the case of Differential Evolution
Adaptive Metropolis (DREAM) [82], [68].
Recent efforts have contributed to the field of inflammation where mathematical models
and a variety of parameter estimation tools have been used to calibrate such models to human
and animal data. These tools include sensitivity analysis, parameter space reduction, and
Latin Hypercube Sampling, [79], [32], [21].
Possible future work to improve our results includes to explore more efficient sampling
algorithms like the ones mentioned above, and the addition of new data to extend the prior
distribution Xtot to enclose higher patient heterogeneity.
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5.0 Applications of data-driven model
5.1 Introduction
The use of mathematical models to develop in silico trials in virtual patients has been
growing in the study of several diseases including cancer, heart disease, and sepsis, [20] [25]
[45] [67]. These trials allow us to reproduce patient responses similar to those observed in
real patients, with the advantage that they can be repeated as many times as needed and
can be used to explore the pros and cons of potential drug therapies.
In this chapter, we begin by using a set of virtual patients constructed in previous
sections to explore patient outcome when experiencing underlying metabolic conditions like
hypoglycemia and hyperglycemia. We also extend our model to include the dynamics of an
NOS inhibitor and explore patient outcome when treating our virtual subjects. Further, we
discuss the importance of both early diagnosis and therapy.
We use logistic regression models to identify key biological processes that can be respon-
sible to classify subjects. In particular, we are interested in distinguishing differences in both
the placebo and treated groups, first between survivors and non-survivors, and within the
non-survivors, differences between septic and aseptic subjects. We also want to understand
the effects of energy and energy-related conditions on patient outcome. Lastly, we explore
the role of anti-inflammatory mediators and glucose. In particular, we explore how high and
low CA and glucose sources affect a virtual population.
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5.2 Inducing hypoglycemia and hyperglycemia
In Section 2.4, we discussed about the role of certain altered metabolic conditions such as
hyperglycemia, hypoglycemia, and hypoxia during sepsis. Because our initial model did not
include any glucose dynamics in it, we artificially modeled these conditions by tuning some
parameters that were involved in ATP availability and in the potential negative effects such
conditions have been reported to present during sepsis. We explore the effects of hypo-
glycemia and hyperglycemia in the baseline population Xtot by following a similar approach
to that done in Section 2.4. However, the fact that our extended model includes glucose
dynamics allows us to induce these conditions in a more direct way. As hypoglycemia is
defined as low glucose levels in the blood, we create a hypoglycemic virtual population by
reducing glucose production rate by 25% by setting sg to 3/4 of its original value in all sub-
jects. Similarly, the pro-inflammatory effects of hypoglycemia can be included by increasing
phagocyte proliferation-activation by 10%. This is achieved by increasing parameter snr by
10% for each patient. The choice of 25% and 10% was arbitrary and they can be changed
to illustrate other possible scenarios.
Similarly, a hyperglycemic virtual population is constructed. As hyperglycemia corre-
sponds to high levels of blood glucose, we increase glucose uptake by 10% by setting pa-
rameter sg to 1.1 of its original value for every virtual subject. Moreover, hyperglycemia is
also known to have negative effects in phagocyte performance, slowing down phagocytosis
and in general phagocytic activity. We include this negative effect by reducing phagocytosis
by 50%, that is, by reducing kpn to half of its original value for every subject in the virtual
population.
We compare these two new virtual populations with a baseline set, which is distributed
into 75% non-survivors and 25% survivors. Table 11 shows the percentage effect of hypo-
glycemia and hyperglycemia when induced in a baseline population of 5000 virtual subjects.
Inducing hypoglycemia leads to an increase in the percentage of non-survivors to 96%. Al-
though not as deadly as hypoglycemia, hyperglycemia also increases the probability of death
to 80%. This is consistent with the observations made in Chapter 2, on which we noted
that hypoglycemia and hyperglycemia benefit sepsis, and that hypoglycemia has a higher
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mortality rate.
Numerical issues were found in 8 of the hypoglycemic and 11 of the hyperglycemic sub-
jects and were taken out of the corresponding population without representing any significant
impact to the results. We observe a transition from healthy and aseptic subjects into the
septic regime in both metabolic conditions. Table 11 also suggest that after inducing these
two conditions into an entirely healthy population, we can expect about 85% mortality from
hypoglycemia and about 21% mortality in hyperglycemic patients.
Table 11: Inducing metabolic conditions in total population Xtot
Baseline Hypoglycemia Hyperglycemia
Health 1252 182 989
Aseptic 3035 2311 2951
Septic 713 2499 1049
Total 5000 4992 4989
Prob. Non-Surv. 75% 96% 80%
The effect of hypoglycemia in the entire population can be seen in the corresponding
envelopes shown in Fig. 37. Insufficient glycogen production after the first 10 hours of
infection, prevents glucose from recovering in hypoglycemic subjects. As a result, low glucose
compromises energy production and with it all the energy dependent processes. In particular,
we observe a reduction in phagocytic activity, as well as in anti-inflammatory mediators,
compromising both pathogen elimination and down-regulation of the inflammatory response.
An important observation is that the baseline population is not free of hypoglcyemic
individuals. As there are some subjects who already have low glucose levels or some other
who could eventually become hypoglycemic because their energy is unable to keep up with
the demand.
Although hyperglycemia in principle could be thought to be beneficial because of the
higher glucose and therefore higher energy levels, in reality hyperglycemia compromises the
effectiveness of phagocytosis. This improper phagocytic activity can be better visualized
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in the envelope trajectory of the energy flux that corresponds to the energy spent during
phagocytosis Φ2, shown in Fig. 38. The envelopes of all model trajectories of hyperglycemic
subjects versus baseline are shown in Fig. 38. In hyperglycemia we also observe an early rise
in anti-inflammatory mediators triggered by the initial glucose uptake that last for about the
first 10 hours. Later on, glucose starts to be transformed into ATP, as an effort to sustain
inflammation. However the poor phagocyte response cannot respond quickly enough to fight
the rise in bacteria.
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Figure 37: Predicted envelopes of model trajectories obtained with both baseline parameters
and inducing hypoglycemia. Baseline trajectories are colored in blue whereas hypoglycemic
trajectories are colored in magenta. The solid blue and magenta lines correspond to the
median of the sampled trajectories and the shaded regions bounded by the dashed lines
enclose the corresponding 5%− 95% confidence intervals.
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Figure 38: Predicted envelopes of model trajectories obtained with both baseline parameters
and inducing hyperglycemia. Baseline trajectories are colored in blue while hyperglycemic
trajectories are colored in orange. The solid blue and orange lines correspond to the median
of the sampled trajectories and the shaded regions bounded by the dashed lines enclose the




The use of NOS inhibitors to treat septic patients has been an entire topic of discussion
over the past two decades, [53], [71]. Although the NOS inhibitor L-NMMA was successful
in the baboons study in [62] obtaining 12 out of 16 survivors, the use of this inhibitor in
human septic patients has been a source of debate. In fact, a phase II study using the
546C88 inhibitor showed promising results in humans [36], but a subsequent phase III trial
was prematurely terminated due to increase in mortality in the treated cohort, [50].
In this section however, we are interested in studying the effect of therapy in the group of
baboons who were administered a continuous infusion of the NOS inhibitor 546C88 L-NMMA
at 12 hours after sepsis induction. A dose of 5 mg/kg/per hour was given for 36 hours (i.e.
until 48 hours after sepsis induction). This inhibitor has been reported to have detrimental
effects including tissue and organ damage, increase in the production of pro-inflammatory
cytokines, and increase in mortality. However, the authors claim they carefully checked for
these and other potential problems and found no negative side effects of 546C88 therapy in
the treated cohort, [62].
For this reason when modeling the dynamics of therapy we only include its inhibitory
effects on the nitric oxide production. This inhibition effect appears on the updated X
equation (56) where kth denotes therapy strength. Therapy itself is modeled by the smooth











(knonN + knodD)− µnoX (56)
S =
1
(1 + e500(12−t)) (1 + e500(t−48))
(57)
The use of 500 in the exponential function in S provides a rapid rise-decay when therapy is
turned on-off. As all subjects were given the same dosage, we fixed drug strength at kth=1000.
Initially the total population Xtot consists of 25% survivors and 75% non-survivors. After
applying therapy to this distribution, we obtain a treated distribution which we will denote
Xtot,th, and it now consists of 46% survivors and 54% non-survivors. If therapy is applied
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exclusively to the non-survivors in Xtot, it results on 30% survivors and the remainder 70%
die, even when treatment is administered. This was the highest effect we observed with
therapy regardless of considering higher therapy strengths. Variations on S can include a
more slow decay rate of drug treatment that can account for the half life of the inhibitor.
However, since the half life of the NOS inhibitor used in the study is about 1 hour, we did
not observe any significant differences in the effectiveness of treatment.
5.3.2 Metropolis algorithm with informative prior on treated subjects
Once again we use the Metropolis algorithm with informative prior to fit individual data and
validate our model. This time the data is taken from the 16 subjects who were treated with
an NOS inhibitor. We use the population distribution Xtot,th as a prior to find a posterior
distribution by following the same procedure described in Section 4.3.4.
Table 12: Metropolis with informative prior: individual fits of treated subjects
Subject Prob. Surv. Prob Non-Surv Subject Prob. Surv. Prob Non-Surv
NS68 37.62% 62.38% S91 96.22% 3.78%
S70 94.62% 5.38% S93 94.52% 5.48%
NS71 23.71% 76.29% NS94 89.78% 10.22%
S72 96.72% 3.28% S95 79.69% 20.31%
S77 96.18% 3.82% S99 98.46% 1.54%
NS78 55.10% 44.9% S102 97.28% 2.27%
S79 95.79% 4.21% S103 99.02% 0.098%
S83 96.73% 3.27% S106 99.14% 0.86%
In Table 12 we summarize the probabilities of survival obtained when fitting each of
the subjects in the treated group with the Metropolis algorithm. Overall the results are
consistent with the actual outcome of the corresponding subject, as survivors are predicted
to survive with high probability and most of the non-survivors are predicted to die with
103
relatively high probability. We note however that there are some cases on which the algorithm
seems to have difficulties deciding between survivor and non-survivor. That is the case of
subject NS78 which is estimated to be a non-survivor with a probability of only 44.89%,
despite the fact that this is originally a non-survivor subject. A similar situation occurs
when fitting subject NS94, which according to the model it has only 10.22% probabilities of
not surviving.
According to the fits, shown in Fig. 39, at the last time points in the data trajectories
of NS78 and NS94 (47 and 72 hours, respectively), lactate decreases and levels off at similar
values to those before treatment making their trajectories similar to survivor trajectories
and hence a lower probability of dying, even after therapy has been stopped. On the other
hand, not only NS68 and NS71 have fewer data points, but also there is a rise in their lactate
data at 23 and 35 hours. This rise is most likely the reason why their lactate trajectories are
predicted to ramp up and saturate at high levels. Although our model is not capturing this
rise in lactate during therapy for the non-survivors, the model is able to predict high lactate
response at a later time and still predicting high probability of not survival for NS68 and
NS71. Work still needs to be done to obtain an earlier rebound in lactate as a consequence
of therapy as suggested by the non-survivor data. However, the model is still able to provide
important insight on the effect of therapy at the population level, as we discuss in Section
5.4.4.
We also note there is a consistent increased behavior in lactate measurements during
therapy across non-survivors, although it appears more evident in NS68, NS71, and NS78.
In fact, when comparing non-survivor trajectories with survivors we note that this elevated
response in lactate does not occur in survivors, as it can been seen in Fig. 40, where we
show the fits and envelopes of 4 of the 12 survivors.
To complement the envelopes of the observed variables, we also present the envelopes
of model trajectories of one of the non-survivor subjects, NS68 in Fig. 41. We note that
by the time therapy is administered to the subject, pathogens are almost completely gone,
leaving tissue damage to be driven mainly by nitric oxide. And as a consequence the fact
that therapy down regulates X helps tissue damage to keep decreasing. This effect indirectly
affects variables such as CA , Ab, and L. However, as soon as therapy is over, nitric oxide
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jumps back in and is followed by tissue damage and lactate. This rebound in D is soon out
of control exhausting the levels of Ab that is in charge of tissue healing.
We also illustrate, how the model performs when fitting survivors by showing the en-
velopes of the model trajectories of S102 in Fig. 42. The model fits well the effect of therapy
in the nitrate trajectory. As a consequence, we note that therapy seems to have an important
effect in tissue damage, allowing all inflammatory effects some time to be down-regulated by
the high CA that can be sustained by both ATPs.
Following the same approach done in Section 4.3.4, we recompute the probabilities of
survival for subjects NS78 and NS94 by fitting their data trajectories using only their first
5 and 6 time points. It is important to note that the fifth time point occurs one hour before
therapy starts and the sixth time point is at 23 hours, while treatment ends until 48 hours.
For subject NS78, the probability of non-surviving improves to be 56.52% when using 5
data points and 52.71% when using 6 data points. For subject NS94, the results also improve
compared to when using all the data points. However, the probabilities of non-surviving are
still considerably low for the 5 and 6 time points.
Table 13: Metropolis with informative prior: individual fits of treated subjects
with 5 and 6 time points
5 time points 6 time points
Subject Prob. Surv. Prob Non-Surv Prob. Surv. Prob Non-Surv
NS78 43.48% 56.52% 47.29% 52.71%
NS94 75.9% 24.1% 56.05% 43.95%
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(a) (b) (c) (d)
Figure 39: Envelopes of model trajectories corresponding to posterior density for treated
subjects (a) NS68, (b) NS71, (c) NS78, and (d) NS94 obtained with Metropolis with infor-
mative prior. Subjects were treated with an NOS inhibitor from 12 hours until 48 hours,
indicated by arrows in the Nitrate panels.
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(a) (b) (c) (d)
Figure 40: Envelopes of model trajectories corresponding to posterior density for treated
subjects (a) S91, (b) S102, (c) S103, and (d) S106 obtained with Metropolis with informative
prior. Subjects were treated with an NOS inhibitor from 12 hours until 48 hours, indicated
by arrows in the Nitrate panels.
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Figure 41: Predicted intervals of model trajectories obtained with metropolis fitting NS68.
The solid red and blue lines correspond to the medians of the sampled trajectories and the
shaded regions bounded by the dashed lines enclose the 5%−95% confidence interval. Insets
show a close-up of the effect of therapy in D,Nit, and X.
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Figure 42: Predicted intervals of model trajectories obtained with metropolis fitting S102.
The solid red and blue lines correspond to the medians of the sampled trajectories and the
shaded regions bounded by the dashed lines enclose the 5%− 95% confidence interval.
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5.3.3 Alternative scenarios of treatment induction
According to the authors in [62], several considerations were made to decide the therapy
protocol implemented in their study. For instance, they first measured mean arterial blood
pressure (MAP) in a pilot group of animals. They observed MAP started to decline between
12-18 h. Second, they also studied induction of increased NOS activity by looking at ni-
trite/nitrate measurements and found increased NOS activity after 4 hours, with an increase
nitrate levels at 8 and 24 hours. Based on these observations, they decided to start infusion
of the NOS inhibitor at 12 hours. Starting therapy at this time has also clinical reasons, as
sepsis diagnosis and therefore therapy usually occurs several hours after pathogen invasion.
Table 14: Alternative therapy protocols
Therapy Interval Health (±35) Aseptic (±34) Septic (±25) Total Prob. Surv.
[12, 48] 2281 2017 698 4996 45.66
[2, 38] 2824 1459 713 4996 56.53
[8, 44] 2671 1638 685 4994 53.48
[10, 46] 2476 1832 685 4993 49.59
[12, 40] 2189 2129 679 4997 43.81
[12, 50] 2346 1906 745 4997 46.95
[12, 60] 2479 1757 760 4996 49.62
[12, 80] 2821 1460 715 4996 56.47
[14, 50] 2152 2128 718 4998 43.06
[14, 60] 2260 2039 688 4987 45.32
[16, 52] 1989 2310 695 4994 39.83
We use our model to explore other possible scenarios including, earlier and later therapy
infusion with 36 hours duration, and shorter and longer therapy duration. We applied
therapy (with kth = 1000) to a subsample of Xtot which initially is distributed with 75%
non-survivors and 25% survivors. We compare these scenarios with the baseline case when
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therapy is administered as in the baboon study from 12 hours until 48 hours, shown in
the first row of Table 14. We computed the standard deviations shown with the formula√
np(1− p), where n is the total number of subjects for each case and p is the probability
of occurrence of health, asepsis, and sepsis. As all results were fairly similar, we took the
average.
Our results suggest that early therapy infusion improves mortality outcome. In fact,
starting therapy at 10 hours and during the same period of 36 hours, results in an increase in
the probability of survival of 3.93%, as shown in the last column of Table 14. If therapy starts
even earlier, at 8 hours after infection, probability of survival improves to 53%. However,
starting therapy too early is unlikely as patients must be diagnosed first. In practice, NOS
inhibitor therapy must be applied not earlier than increased NOS activity starts. However,
our model does not account for this and it predicts higher survival when treatment starts as
early as 2 hours after infection.
On the other hand, starting therapy at 14 hours decreases survival probability to 43.06%,
even if treatment is administered during the same 36 hours period of time. If therapy is
administered much later at 16 hours, probability of survival decreases to 39.83%, even if
treatment is extended for the same duration of 36 hours. Lastly, we also observed that
starting at 12 hours and administering therapy for only 34 hours instead of 36 hours, does
not significantly change survival. Similarly, extending duration of therapy until 50 hours and
starting at 12 hours, does not significantly improve survival. However, our model suggest
that further increasing therapy duration improves survival. In fact, therapy needs to be
applied from 12 to 60 hours to increase survival to 49.62% and up to 80 hours for a survival
probability of 56.47%.
It is clear from Table 14 that with early therapy intervention we should expect a positive
effect on aseptic patients. However, sepsis does not seem to be highly affected by therapy.
Work still needs to be done to explore further therapeutic routines. For instance, optimal
control techniques can be applied to find best treatment strategies that can include intervals
of therapy application while minimizing potential side effects.
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5.4 Logistic regression: identifying outcome from patient characteristics
5.4.1 Preliminaries
Logistic regression is a statistical tool similar to linear regression that is commonly used
to describe the relation between one binary or dichotomous variable Y and one or more
independent variables or predictors X1, X2, · · · , Xk. The dependent variable is dichotomous,
because it only assumes binary values, such as 0 or 1, male-female, pass-fail, etc. Logistic
regression is commonly used in the medical scientific community to evaluate risk factors in
patient outcome [65], [20], [78]. Seymour et al. used logistic regression to relate patient
characteristics to outcomes, and thus estimate the probability of a patient dying of sepsis,
[65].
Mathematically, logistic regression models how the binary variable Y depends on the






= b0 + b1X1 + · · ·+ bkXk (58)
The distribution of Y is assumed to be binomial and p is the probability of success, i.e.
p = P (Y = 1). The left hand side of equation (58) is called the logit function which models
the dependent variable by a linear combination of independent variables, and it corresponds
to the log of the odds of an event occurring. The coefficients b0, b1, · · · , bk are selected in
such a way that maximize the likelihood of predicting with high probability for observations
belonging to one class, say 1, and low probability for observations belonging to the other
class, say 0. This process is called maximum likelihood estimation, and is used in logistic
regression to identify the strongest linear combination of independent variables that increases
the likelihood of detecting the observed outcome.
It is important to understand the difference between odds and probability. The odds
correspond to the ratio of the probability that an event occurs over the probability that the









For example, if the probability of an event happening is 0.75, then odds of the event
occurring is 0.75/0.25 = 3. In other words, the event will occur 3 times for every time the
event does not occur.
Combining equations (59) and (58), we obtain a formula for the odds that an event
occurs depending on the predictor variables and their coefficients:
Odds = eb0+b1X1+···+bkXk (60)
Using equations (59) and (60) we also obtain a formula for the probability of the event





To illustrate how to interpret the resulting coefficients b0, b1, · · · , bk given in the logistic
regression, we consider the following example. Suppose we are modeling a binary dependent
variable that takes either the values diabetes or healthy. Suppose that p = P (Y = 1) is
the probability of a patient becoming diabetic. And that we have several predictor variables
X1, · · · , Xk. In particular, we want to determine whether or not increasing one of the
predictor variables, say X1 =glucose, by one unit has any influence in the outcome of the
dependent variable. Suppose that for this variable we obtained the coefficient b1 = 1.6. Then





= b0 + (1.6)g + · · ·+ bkXk (62)






= b0 + (1.6)(g + 1) + · · ·+ bkXk (63)














) = e1.6 = 4.953 (65)
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In other words the OR corresponds to the exponential of the regression coefficient ebj .
In our example, the OR tells us that by holding fixed all the other predictor variables and
increasing glucose by one unit, the odds of becoming diabetic increase by about 395.3%.
In this section we use logistic regression to determine which parameters have an influence
in the model output. In particular, we will consider three different scenarios (see Fig. 43):
1. When the total virtual population is classified into either survivors or non-survivors.
2. When the non-survivor virtual population is classified into either septic or aseptic.
3. When the non-survivors that undergo treatment is classified into either survivors or
non-survivors.
Figure 43: Diagram of three different scenarios studied with logistic regression.
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5.4.2 Logistic regression on survivors and non-survivors non-treated
In this section, we consider a random sub-sample of Xtot. Every subject from this sample
can either be a survivor or a non-survivor depending on the model output. Survivors are
those subjects whose model trajectories converge to the healthy steady state. Whereas non-
survivors are those subjects whose model trajectories are either septic or aseptic. Each
virtual subject in this population consists of 55 parameters, that when plugged into our
model have associated either a survivor or a non-survivor trajectory. Our goal here is to
determine which parameters out of the 55 can be considered as patient outcome predictors.
As this sub-sample contains parameters with different orders of magnitude, we standard-
ize it by subtracting the mean and dividing by the standard deviation. We will do this
same step in all three cases where we used logistic regression in the following sections. We
let p be the probability that a subject will survive, i.e. p = P (Survives = 1) and use the
Classification Learner App in Matlab 2020a to run a logistic regression model with 55 pre-
dictor parameters and 5-fold cross validation to avoid over-fitting. With the 55 predictor
parameters, the model has a classification accuracy of 93.1%. Interestingly enough, reducing
the number of predictor parameters to 12 does not significantly lower the accuracy, as the
accuracy of classification in this case is 86.5%. The choice of these 12 parameters was based
on a threshold of 1 in the magnitude of their corresponding estimated coefficients given in
the logistic regression with 55 variables.
Higher estimates have higher contribution to predict patient outcome. All of these 12
parameters had a p-value well below 0.05 but their standard error were relatively high due
to the large number of variables used. We run logistic regression again but this time only
considering these 12 parameters as possible predictor variables. Their corresponding p-values
were again below 0.05 indicating that they are still statistically significant. Moreover, all
their corresponding tstat values are above 2 in magnitude confirming they are statistically
significant, according to the Wald test. A summary of the results from logistic regression
including coefficient estimates, tstats, odds ratios, and 95% confidence intervals are shown
in Table 15.
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Table 15: Logistic regression summary for non-treated subjects when classifying subjects
between survivors and non-survivors
Variable Coefficient tstat Odds 95% CI Odds % of change
(Intercept) -0.250 -15.110 0.779 ( 0.754, 0.804) -22.114
c2 -1.762 -74.541 0.172 ( 0.163 , 0.179) -82.835
αx -1.014 -56.727 0.363 ( 0.350 , 0.375) -63.714
knod -0.911 -49.741 0.402 ( 0.387, 0.416) -59.805
kdn -0.799 -42.695 0.450 ( 0.433 , 0.466) -55.033
c3 -0.752 -43.425 0.471 ( 0.455 , 0.487) -52.862
kpg -0.736 -38.960 0.479 ( 0.461, 0.497) -52.089
µgly -0.639 -36.665 0.528 ( 0.510 , 0.546) -47.196
kA -0.622 -34.951 0.537 (0.518 , 0.555) -46.314
µno 0.582 33.178 1.790 ( 1.729, 1.853) 79.039
kpn 0.639 36.234 1.895 ( 1.830 , 1.961) 89.475
xdn 1.366 68.548 3.919 ( 3.769, 4.075) 291.906
µA 2.768 92.037 15.934 ( 15.021 , 16.901) 1493.413
The confusion matrix shown in Fig. 44a, summarizes the accuracy of the logistic regres-
sion algorithm in predicting surviving versus non surviving with the 12 parameters mentioned
above. In the main diagonal (colored in blue) we observe the True Positives (TP) and the
True Negatives (TN), respectively. 85.5% are TP which corresponds to the percentage of sub-
jects that did not survive and were correctly classified by the algorithm as non-survivors. On
the other hand, 87.5% are TN which corresponds to the percentage of subjects that survived
and were correctly identified by the algorithm as survivors. In the anti-diagonal (colored in
red), we observe the False Positive (FP) and False Negative (FN) groups. In the FP, 12.5%
corresponds to the percentage of subjects that survive but were incorrectly classified by the
algorithm as non-survivors. Whereas 14.5% is the percentage of FN, which corresponds those
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Table 16: Standard deviation of significant parameters when classifying non-treated
subjects between survivors and non-survivors
Parameter STD Parameter STD
c2 43.279 µgly 0.3306
αx 0.52665 kA 0.0014045
knod 5894.4 µno 4172.9
kdn 0.012103 kpn 2.9452
c3 0.86863 xdn 0.10641
kpg 0.047989 µA 5.8403
subjects that did not survive but were incorrectly classified by the algorithm as survivors.
As shown in Fig. 44b, the discrimination of these 12 predictor variables for survival as
expressed by the receiver operating characteristic area under curve (ROC) was 0.94. The
ROC gives the rate of successful classification by the logistic model. The higher the AUC the
better the algorithm is at predicting survivors and non-survivors. The AUC is determined
by the threshold of classification given by having a false positive rate of 0.13 and a true
positive rate of 0.85. This threshold was automatically chosen by the classification learner
algorithm.
Although many biological processes are condensed into the dynamics of our model, from
our results we learned that some energy related processes have an important role in deter-
mining patient outcome. Its large estimate coefficient indicates that µA is the parameter
that better predicts outcome between survivors and non-survivors. In fact, holding all other
parameters fixed and increasing one standardized unit of µA results in an increase in the odds
of surviving by 1493.4%, where one standardized unit of µA is 5.8403 units. The standard
deviations of all 12 parameters are shown in Table 16.
As we pointed out in Section 3.5, µA is the energy rate constant. The exact role it plays
117
(a) (b)
Figure 44: (a) The confusion matrix contains information about actual and predicted classi-
fications between survivors and non-survivors non-treated. (b) The ROC and AUC curve for
the classification between survivors and non-survivors non-treated. The red point indicates
the true positive rate and true positive rate used in the classification. The area under the
curve AUC provides a sense of the degree or measure of separability of the model. The
higher the AUC, the better is the model in classifying survivors and non-survivors.
in the dynamics of our model is not straight forward as µA is also involved in the production
and depletion of both ATPs, as it was noted in equations (28) and (29).
The high estimates for parameters kpn, and c2 indicate that phagocytosis and the energy
required for this process to take place are also part of the parameters with higher contri-
bution to predict patient outcome. Although its odds ratio suggests that an increase of
one standardized unit of kpn represents an increment of 89.4% in the odds of surviving, the
quartile plots indicate that survival is better attained when it lies within the second and
third quartile. Quartile plots for the 12 most significant parameters are shown in Fig. 45.
On the other hand increasing c2 has a negative effect in survival. In fact, there is an 82.8%
reduction in the odds of survival per increment of one standardized unit of c2. This says that
if all other parameters were to be kept fixed and there is a increment in the energy consumed
in pathogen elimination through phagocytosis, we should expect a reduction in the odds of
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surviving. This negative effect is even more significant for higher values of c2, as detailed in
Fig. 45.
Tissue damage marker is also an important predictor, mostly determined by its half satu-
ration value xdn. In fact, this parameter ranks second in terms of odds ratios. In the quartile
plots, we observed that the higher this half saturation can get, the better the percentage of
survival. In fact, 67% of the subjects whose xdn value lies in the fourth quartile survive. An-
other tissue damage related parameter that was highlighted in the logistic regression results
was αx. This parameter however, does not have an intrinsic biological meaning as it is used
as a scaling parameter to balance the number of pathogens and molecules of nitric oxide.
However we interpret that the higher its value, the more impact nitric oxide has on tissue
damage production, which is consistent to the higher percentage on non-survivors when αx
lies over the third and fourth quartiles shown in Fig. 45.
The odds ratio column shown in Table 15 shows the effect that each parameter contributes
to survival when all the other parameters are held fixed. On the other hand, the quartile
plots indicate the survival percentage for a portion of the ensemble with a specified range
of each parameter, without holding any restrictions on the other parameters. Lastly, the
parameter densities shown in Fig. 46 provide a measure of the frequency of each parameter
value taken by members of the ensemble.
Finally, it is important to note that although the quartile plots indicate that higher kpg
is associated to higher survival probability, it is unclear what is the combination with the
other parameters that will lead to such higher probabilities to explain this counter intuitive
behaviour. However, in Fig. 47d we note that for survivors it is more likely to observe higher
values of µA. This suggest that if we observe a patient whose pathogen load growth is high,
we would recommend to increase the energy rate to improve chances of survival. This does
not occur within the non-survivor population as we can see in Fig. 47a, where these two
parameters are positively correlated.
Overall parameters are not highly correlated. The only pair correlation higher than 0.5
was between sg and kA in the survivor population where they are positively correlated with
a correlation coefficient of 0.58. A scatter plot of these two parameters is shown in Fig.
47f. Additionally in Fig. 47 we also present pair scatter plots of µA vs kpg and µA vs xdn
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Figure 45: Quartiles of most contributing parameters when non-treated subjects are classi-
fied between non-survivors and survivors. Survivors are colored in blue whereas non-survivors
are colored in orange.
within the non-survivor group in (a) and (b), respectively. Similarly, scatter plots of these
parameters within the survivor cohort are also shown in (d) and (e), respectively. These
parameters were shown to be relevant to decide patient outcome in the logistic regression
results.
5.4.2.1 Envelopes for non-survivors and survivors The envelopes of the two distri-
butions of survivors and non-survivors are depicted in Fig. 48. There is a clear distinction
between survivors and non-survivors in the ATP trajectories that is more evident after the
first few hours. During the first 3 hours both Ab and An have similar transient behavior.
However, there is a rebound in both survivor ATPs that starts at about 4 hours after in-
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Figure 46: Densities of most contributing parameters when non-treated subjects are classi-
fied between non-survivors and survivors. Survivors are colored in blue whereas non-survivors
are colored in orange.
duction of infection. A similar rebound is observed in non-survivor An at a later time at
about 11 hours. This rebound is however not strong enough and it soon stabilizes to a low
energy steady state. This difference in energy between the two populations is in part a result
of different glucose levels, where survivors have an overall higher glucose level compared to
non-survivors.
Although more phagocyte activity is present during the first 10 hours in the survivor
trajectories, the fact that enough ATP is available for survivors during this initial period of
time, fuels their anti-inflammatory response CA to make it more efficient in maintaining a
balance in the inflammation process. These elevated levels on anti-inflammatory mediators




Figure 47: Pair correlations of some parameters in the survivors and non-survivors cohorts.
(a) µA vs kpg in non-survivors, (b) µA vs xdn in non-survivors, (c) sg vs kA in non-survivors,
(d) µA vs kpg in survivors, (e) µA vs xdn in survivors, and (f) sg vs kA in survivors.
Ab in survivors rapidly takes care of tissue damage as it can be observed in the bifurcation
occurring at about 5 hours between the two D trajectories. The same bifurcation occurs
at different times also in the L, LPS, X, and Gly trajectories. In lactate this bifurcation
suggests a shift on energy metabolism from aerobic to anaerobic respiration in non-survivors.
This shift is partial as some ATP is still produced through phosphorylation.
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Figure 48: Predicted intervals of model trajectories obtained with parameters from a sur-
vivors and non-survivors distributions from non-survivors non-treated distribution. Non-
survivors envelopes are colored in orange whereas survivors envelopes are blue. The solid
red and blue lines correspond to the medians of the sampled trajectories and the shaded
regions bounded by the dashed lines enclose the 5%− 95% confidence interval.
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5.4.3 Logistic regression on non-survivors non-treated: septic and aseptic
As we have already discussed earlier, our virtual population of non-survivors non-treated can
be separated into either septic or aseptic individuals. However, it is unclear what specific
mechanisms differentiate one group from the other. This is once again a perfect opportunity
to use logistic regression to model patient outcome from patient characteristics. We begin by
randomly selecting from Xtot column vectors to form a sub matrix Xnsnt of size 55× 20000,
where nsnt stands for non-survivors non-treated. We then use our extended model to classify
virtual subjects into either septic or aseptic. As a result, we obtain that 3928 (19.64%)
are classified as septic and 16072 (80.36%) are aseptic. Because this is again a binary
classification, we extend Xnsnt by one extra column and assign 1 to septic subjects and 0 to
aseptic. We standardize Xnsnt as we did in the previous section and use logistic regression
initially with 55 features with 5-fold cross validation, to obtain 93.6% of accuracy. We then
select the parameters whose coefficient estimate is larger in magnitude than 1 and obtained
a classification accuracy of 89.9%. This is summarized in the confusion matrix shown in
Fig. 49, where 95.9% aseptic were correctly classified while the other 4.1% where incorrectly
classified as septic. Similarly, 64.8% of the septic subjects were correctly classified whereas
the other 35.2% were incorrectly classified as aseptic. Moreover, the area under the curve
ROC was 0.94.
As it can be observed in Table 18, both pathogen growth rate and energy rate, play a
fundamental role in predicting outcome of patients between septic and aseptic. In fact, an
increment of one standardized unit of kpg, i.e. an increment of 0.0489 units in the rate of
pathogen growth, results in an increment in the odds of becoming septic by 1160%. Table
17 contains the standard deviations of the 5 selected parameters.
We observe in Fig. 51 that septic patients are more likely to have higher kpg values than
aseptic patients. This is consistent with the results found in Chapter 2. In fact, 38.52%
of the non-survivor subjects whose kpg lies within the fourth quartile are septic, while the
other 61.48% are aseptic. In contrast, only 2.96% of the non-survivors whose kpg lies within
the first quartile is septic. We also observe that patients with lower µA have higher risk of
becoming septic. In fact, for every time µA increases 5.6613 units, the odds of becoming
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(a) (b)
Figure 49: (a) The confusion matrix contains information about actual and predicted clas-
sifications between non-survivors non-treated septic and aseptic. (b) The ROC and AUC
curve for the classification between non-survivors non-treated septic and aseptic. The red
point indicates the true positive rate and true positive rate used in the classification. The
area under the curve AUC provides a sense of the degree or measure of separability of the
model. The higher the AUC, the better is the model in classifying non-survivors between
septic and aseptic.
septic decrease by 90.561%.
We note that here the two groups under consideration are non-survivors and therefore,
as we mentioned in the previous section, it is expected that µA tends to be on the lower
side for both groups. However, as seen in Fig. 52, septic patients are more likely to have
smaller µA compared to aseptic subjects. Also, according to the quartile plots, 34.58% of
the subjects whose µA lies in the first quartile are septic, while only 8.66% of the subjects
whose µA lies within the fourth quartile are septic.
Parameter c2 is the proportionality rate of the phagocytosis energy flux. And our results
suggest that the more energy is spent during this process, the higher the risk of sepsis. In
fact, holding all variables fixed, for every time c2 increases one standardized unit, i.e. 43.363
units, there is 447.278% increase in the odds of becoming septic. Similar conclusions can be
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made from the estimates of µm and kpm, which are involved in the elimination of pathogens
through non-specific means.
Again parameters are not highly correlated across the two populations. However as a
matter of comparison we also show the pair scatter plot of kpg vs µA for septic in Fig. 50a
and for the aseptic population in Fig. 50b. Although not at a high value kpg vs µA are
positively correlated in the aseptic group with a correlation factor of 0.36.
(a) (b)
Figure 50: Pair correlations septic and aseptic. (a) µA vs kpg in the septic population, (b)
µA vs kpg in the aseptic population.









Table 18: Logistic regression summary for non-survivors after treatment that are classified 
between septic and aseptic
Variable Coefficient tstat Odds 95% CI Odds % of Change
(Intercept) -2.920 -67.007 0.054 (0.049, 0.058) -94.605
µA -2.360 -52.890 0.094 ( 0.086, 0.103) -90.561
kpm -1.094 -36.365 0.335 ( 0.315 , 0.355) -66.501
µm 0.985 33.412 2.677 (2.526, 2.836) 167.716
c2 1.700 45.924 5.473 ( 5.089 , 5.884) 447.278
kpg 2.534 55.998 12.607 (11.537, 13.777) 1160.712
Figure 51: Quartiles of most contributing parameters for non-survivors non-treated when
classified between septic and aseptic. Septic are colored in red whereas aseptic are colored
in green.
5.4.3.1 Envelopes for septic and aseptic As the two groups here are non-survivors
their envelopes are fairly similar in most of the trajectories. By definition the P envelopes in
aseptic are converging to baseline levels while in sepsis P saturates at its carrying capacity.
Inflammatory variables such as tissue damage, nitric oxide, and lactate are basically the same
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Figure 52: Densities densities of most contributing parameters for non-survivors non-treated
when classified between septic and aseptic. Septic are colored in red whereas aseptic are
colored in green.
across the two groups. However important differences are observed in the An trajectories,
indicating that this form of ATP could be determinant for separating septic from aseptic.
We note an early An recovery in the aseptic group starting at about 3 hours. This rebound
continues up until 12 hours, and even though it levels down again, it converges to a much
higher value than for those in the septic cohort. This difference in An is also clear on the way
phagocytes fight the infection, as there is a much higher response in phagocytic activity in
the aseptic group. This phagocytic activity is controlled by an also higher anti-inflammatory
response, which is even more stronger in aseptic after the first hour and continues until the
end of the simulation. Having this higher CA response in aseptic, allows them to at the very
least take care of the infection, by eliminating pathogens out of the system within the first
two hours. However, the anti-inflammatory response fails to control the other inflammatory
markers, hence the high inflammation and tissue damage lead to the eventual death of the
aseptic population.
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Figure 53: Predicted intervals of model trajectories obtained with parameters from a septic
and aseptic distributions from non-survivors non-treated distribution. Septic envelopes are
colored red whereas aseptic envelopes are green. The solid red and green lines correspond
to the medians of the sampled trajectories and the shaded regions bounded by the dashed
lines enclose the 5%− 95% confidence interval.
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5.4.4 Logistic regression on non-survivors with therapy
We are interested in determining parameters that can be used to predict patient outcome.
In particular, in this section our goal is to identify key parameters that can predict patient
outcome when therapy is administered. We start by taking a random sub-sample of non-
survivors from the total distribution Xtot. We introduce therapy to this sub-sample the same
way it was described in Section 5.3.1. As patient outcomes are binary - either survivor or
survivor- we assign 1 to survivors and assign 0 to those that do not survive; we then use a
logistic regression model to determine the parameters that better predict a patient’s outcome
after treatment is administered.
As different parameters have different orders of magnitude, we standardize the sub-
sample parameter matrix by subtracting the mean and dividing by the standard deviation,
so that every parameter would have zero mean and standard deviation one. Using the
Classification Learner App in Matlab 2020a with all 55 parameters as predictor variables
and with a 5-fold cross validation to prevent over fitting, we obtain 83.1% of accuracy. That
is, 83.1% of the total number of subjects were correctly classified by the logistic regression
model.
Many of the resulting estimate coefficients had a p-value well below 0.05. But just some
of them had a coefficient with relatively high magnitude compared to the rest. This could
be due to the large amount of predictor variables that were used in the model. We observe
that there are 19 parameters whose corresponding coefficients are larger in magnitude than a
threshold of 0.4. These parameters also coincide with those with the smallest p-value, which
indicates that they are statistically significant.
In order to reduce variability and therefore to obtain more accurate coefficient estimates,
we run the logistic regression algorithm again but this time only using these selected 19
parameters. The accuracy of the model is still considerably high at 81.5% when using
only these 19 parameters. The logistic regression results of the model along with these
19 predictors are summarized in Table 19. The tstat column corresponds to the coefficient
estimate divided by its standard error and according to the Wald test, predictors whose tstat
magnitude is larger than 2 indicate that they are statistically significant. This is consistent
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to their corresponding low p-value (p-value< 0.05).
We obtained that the energy rate µA again plays a major role in predicting patient
outcome in treated subjects. This can be seen by its large value of the coefficient estimate
shown in Table 19. Its contribution is even more evident when looking at the percentage of
change, which indicates that an increment of one standardized unit of µA, (i.e. 5.69 units),
increases the odds of surviving by about 576.7%. Fig. 56 suggests that patients with larger
µA, in particular within the fourth quartile, are more likely to survive after therapy. This is
also seen in Fig. 55, which depicts the parameter densities of most contributing parameters.
Our results also suggest that treatment is more likely to reduce mortality in subjects
whose pathogen growth rate lies within the first quartile Q1, i.e. when kpg is between 0.06
and 0.11. Also, the odds ratio of kpg is 0.31, which indicates that the odds of surviving
after therapy decrease by about 68.4% per increment of one standardized unit of kpg. This
means that an increment of kpg by one standard deviation i.e., 0.049, results in a decrease
on the odds of surviving by about 68.4%. The standard deviations of the most contributing
parameters can be found in Table 20.
Overall parameters are not highly correlated across the two populations of survivors and
non-survivors. However we show the pair scatter plot of kpg vs µA for non-survivors in Fig.
54a and for the survivors population in Fig. 54b. Although not at a high value, kpg vs µA
are positively correlated in the survivor group with a correlation factor of 0.37 and in the
non-survivor group with a correlation factor of 0.22.
As the intuition may suggest, the model reveals that patients whose tissue damage re-
mains under control have better odds of surviving if treatment is administered. In particular,
sustaining lower levels of tissue damage production, which is governed by kdn and αx, as well
as higher half tissue damage accumulation xdn can improve survival in treated patients. This
is also illustrated on the quartiles plots shown in Fig. 56.
The confusion matrix shown in Fig. 57a, summarizes the accuracy of the logistic regres-
sion algorithm in predicting surviving versus non surviving with the 19 parameters mentioned
above. We note that 89.8% of subjects that did not survive after treatment were correctly
classified, whereas the other 10.2% were incorrectly classified as survivors. Similarly, 60.8%
of survivors were correctly classified and the other 39.2% were incorrectly classified as non-
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(a) (b)
Figure 54: Pair correlations of some parameters for non-survivors treated that survive or do
not survive. (a) survivors µA vs kpg, (b) non-survivors µA vs kpg.
survivors.
Lastly, the ROC curve and the AUC shown in Fig. 57b provide complementary infor-
mation to validate the accuracy of the algorithm. The ROC gives the rate of successful
classification by the logistic model. In this case the AUC=0.88, which is determined by the
threshold of classification given by the coordinate point (0.39,0.9) in the false positive rate
vs true positive rate plane. This threshold is automatically chosen by the algorithm.
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Table 19: Logistic regression summary for non-survivors after treatment that are classified
between survivors and non-survivors
Variable Coefficient tstat Odds 95% CI Odds % of Change
(Intercept) -1.749 -97.902 0.174 ( 0.168 , 0.180 ) -82.608
kdn -1.596 -82.554 0.203 ( 0.195 , 0.211 ) -79.727
kpg -1.151 -66.535 0.316 ( 0.306 , 0.327 ) -68.373
knod -0.991 -62.541 0.371 ( 0.360 , 0.383 ) -62.895
c2 -0.921 -54.527 0.398 ( 0.385 , 0.411 ) -60.194
αx -0.874 -59.463 0.417 ( 0.405 , 0.429 ) -58.272
cg -0.783 -54.806 0.457 ( 0.444 , 0.470 ) -54.304
µc -0.721 -49.835 0.486 ( 0.473 , 0.500 ) -51.362
C∗ -0.645 -44.738 0.525 ( 0.510 , 0.540 ) -47.524
µm -0.513 -36.920 0.599 ( 0.583 , 0.615 ) -40.138
c4 -0.440 -33.551 0.644 ( 0.628 , 0.661 ) -35.608
µn -0.353 -26.672 0.703 ( 0.685 , 0.721 ) -29.727
c3 -0.349 -26.134 0.706 ( 0.687 , 0.724 ) -29.447
kA -0.251 -19.136 0.778 ( 0.758 , 0.798 ) -22.218
kpn 0.296 22.390 1.345 ( 1.311 , 1.381 ) 34.514
kcn 0.461 33.907 1.586 ( 1.545 , 1.629 ) 58.627
kpm 0.596 42.669 1.815 ( 1.766 , 1.865 ) 81.479
µno 0.908 59.367 2.480 ( 2.407 , 2.556 ) 148.042
xdn 1.118 69.961 3.058 ( 2.964 , 3.156 ) 205.835
µA 1.912 84.706 6.768 ( 6.475 , 7.074 ) 576.769
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Table 20: Standard deviation for parameters in non-survivors treated
Parameter STD Parameter STD
kdn 0.012 µn 0.244
kpg 0.049 c3 0.857
knod 5890.5 kA 0.001
c2 43.119 kpn 3.024
αx 0.513 kcn 20.422
cg 0.777 kpm 8.45e-5
µc 2.405 µno 4233.8
C∗ 0.824 xdn 0.107
µm 0.001 µA 5.69
c4 850.47
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Figure 55: Densities of most contributing parameters for non-survivors after treatment.
Non-survivors are colored in maroon whereas survivors are colored in light blue.
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Figure 56: Parameter quartiles of most contributing parameters for non-survivors after treat-
ment. Non-survivors are colored in maroon whereas survivors are colored in light blue
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(a) (b)
Figure 57: (a) The confusion matrix contains information about actual and predicted clas-
sifications. (b) The ROC and AUC curve for non-survivors after treatment. The red point
indicates the true positive rate and true positive rate used in the classification. The area
under the curve AUC provides a sense of the degree or measure of separability of the model.
The higher the AUC, the better is the model in classifying survivors and non-survivors after
treatment.
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5.4.4.1 Envelopes for non-survivors treated: survivors and non-survivors In
Fig. 58 we observe that there is a clear separation between survivors and non-survivors in
the CA trajectory even before treatment was administered. This early anti-inflammatory re-
sponse is key in separating the two groups as it sustains inflammatory markers at reasonably
lower levels, so that therapy could be more efficient and improve survival. In fact, treatment
seems to be more efficient on those subjects whose pathogens are almost completely elim-
inated around time of drug injection. Once pathogens are sufficiently low, tissue damage
depends mostly on X. Then, during the time therapy is applied, from 12 h to 48 h, low levels
of X allow tissues to heal. Further, because pathogens are almost eliminated, and damage
is on track of recovery, energy can be spent in fueling CA, which in turn down-regulates
phagocytes and other inflammatory markers. In summary, a combination of high levels of
anti-inflammatory mediators with proper energy availability seems to play a major role in
the path of recovery if treatment is administered.
5.4.4.2 Envelopes for non-survivors treated: septic and aseptic The non-survivor
cohort, can be further classified between septic and aseptic. The corresponding envelopes
are shown in Fig. 59. We observe that sepsis is associated to lower phagocytic activity
due to An depletion. In the aseptic group, pathogens are almost eliminated at the time of
therapy induction and therefore tissue damage is depending only on nitric oxide. Therapy
then allows tissue damage in aseptic to slightly recover or at least to grow at a slower pace
compared to septic subjects. This allows Ab to recover, as it is no longer needed to fight
P anymore. A small rebound in glucose also helps the recovery of An, which can be used
to produce N and CA to keep balancing inflammation. However, the continuous pathogen
replication in sepsis requires more and more activation of phagocytes which leads to high
levels of X and L.
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Figure 58: Predicted intervals of model trajectories obtained with parameters distributions
of non-survivors treated. After treatment subjects either survive or die. Non-survivors
envelopes are colored maroon whereas survivors envelopes are light blue. The solid maroon
and light blue lines correspond to the medians of the sampled trajectories and the shaded
regions bounded by the dashed lines enclose the 5%− 95% confidence interval.
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Figure 59: Predicted intervals of model trajectories obtained with parameters distributions
of non-survivors treated. Non-survivors are either septic or aseptic. Aseptic are colored in
green and septic are in red. The solid red and green lines correspond to the medians of
the sampled trajectories and the shaded regions bounded by the dashed lines enclose the
5%− 95% confidence interval.
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5.5 The role of anti-inflammatory mediators and glucose
In this section we explore different scenarios where we vary either the anti-inflammatory
source parameter sc or the glucose intake parameter sg. With this, we aim to understand
the individual role of CA and glucose in an entire population. In particular we consider four
cases: low sg, high sg, low sc and high sc.
Our model suggests that increasing the source of anti-inflammatory mediators (high sc)
could lead to two different outcomes. In some cases higher CA could be beneficial as inflam-
mation is controlled, down-regulation of nitric oxide production occurs and consequently di-
minishing collateral tissue damage. However, in some other cases, higher anti-inflammation
over inhibits phagocytic activity, compromising pathogen elimination and in turn, septic
cases increase. Because phagocytes are highly inhibited, the only resource for pathogen
elimination is non-specific killing. This can be observed in the compromised N trajectory
after 10 hours, and the increased Φ1 shown on Fig. 60. These results are also consistent
to the findings in [61]. The results of high anti-inflammatory source are shown in the last
column of Table 21.
On the other hand, lowering sc does not show a significant difference in neither the dis-
tribution of cases between health, septic, and aseptic nor in the probability of survival. This
is shown in Table 21 where we decreased the anti-inflammatory source sc by 75% in every
subject. The reason why decreasing sc does not have a major impact in the population is
because there is enough circulating CA whose production has already been triggered as a
response to phagocyte activation and tissue damage. This is a result the relatively large es-
timates in parameters like kcn, µc, and sc, which suggest a relatively rapid anti-inflammatory
response that dominates in the process.
We also explored the potential consequences of varying glucose intake. We note that
energy plays a major role in patient outcome and in the dynamics of our model. As a matter
of fact, for the high sg case, an increment of 20% in the glucose source parameter, sg leads
to a reduction in mortality of 32%. Such mortality reduction mostly coming from aseptic
subjects that are able to recover from over-inflammation due to better ability to heal tissue
damage as seen in Fig. 61. On the other hand, lowering glucose availability (low sg) results
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on a significant increment in mortality of 18.8% with respect to baseline. A combination of
poor anti-inflammatory mediators and insufficient energy to fuel phagocytosis leads to an
increment of 287% in septic cases. This was obtained by reducing sg by 20% for each subject
in the virtual population.
Table 21: Exploring role of glucose and anti-inflammatory mediators
Baseline Low sg High sg Low sc High sc
Health 1252 309 2804 1248 1438
Aseptic 3035 2623 1684 3063 2486
Septic 713 2049 507 689 1064
Total 5000 4981 4995 5000 4988
Prob. Non-Surv. 75% 93.8% 43.86% 75% 71.17%
Figure 60: Predicted intervals of model trajectories obtained after CA enhance by increasing
sc by 400% with respect to baseline. Here we are displaying only those variables that show
significant differences between the two groups. The solid blue line corresponds to the median
of the baseline trajectories, whereas the magenta solid line corresponds to the modified
distribution with higher sc. The color shaded regions enclose the 5% − 95% confidence
interval.
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Figure 61: Predicted intervals of model trajectories obtained after enhancing glucose intake
by 20%. Here we are displaying only those variables that show significant differences between
the two groups. The solid blue line corresponds to the median of the baseline trajectories,
whereas the green solid line corresponds to the modified distribution with higher sg. The
color shaded regions enclose the 5%− 95% confidence interval.
143
Figure 62: Predicted intervals of model trajectories obtained after lowering glucose intake
by 20%. The solid blue line corresponds to the median of the baseline trajectories, whereas
the yellow solid line corresponds to the modified distribution with lower sg. The color shaded
regions enclose the 5%− 95% confidence interval.
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5.6 Discussion
In this chapter we started by using our extended model and the virtual population Xtot
constructed in Section 4.3.3, to explore how hypoglycemia and hyperglycemia affect the
virtual population while fighting a pathogenic infection. As expected, because of the work
presented in Section 2.4, hypoglycemia has a major impact in mortality. Patients that
under normal circumstances would have survived, were highly impacted by the induction
of hypoglycemia and ended up dying. Although at a lower extend than hypoglycemia,
hyperglycemia also proves to benefit sepsis resulting in an increment in mortality.
With our model, we also introduced the dynamics of an NOS inhibitor to be given at 12
hours after pathogen infection and during a continuous infusion that lasted until 48 hours.
We introduced therapy into our virtual population Xtot and compared the results with the
available data of 16 baboons who were treated with the NOS inhibitor at the mentioned
time. Using a Metropolis algorithm with informative prior, we fitted the treated subjects
data and obtained probability of survival that were, in most of the cases, consistent with the
actual data. Work still needs to be done to improve the fits in non-survivors, especially in
lactate measurements. Our model does not reflect the rise in lactate during therapy that is
observed in three of the four non-survivors who were treated.
We also explored different times of therapy induction and our results suggest that early
diagnosis and therefore early therapy can have a major role in reducing mortality. In fact,
we found that introducing therapy after 8 hours of infection could improve survival by about
7%. However some limitations are observed in our model as it predicts higher survival when
treatment is induced as early as 2 hours, whereas in practice such an early treatment is
not realistic when treating real patients. Presumably there has to be certain period of time
between infection, diagnosis, and treatment. Moreover, based on the observations made in
the original baboon study, no side effects were observed. However, NOS inhibitors can cause
a variety of side effects that were not contemplated into our model. Future directions can
include such side effects when calibrating the model with potential new data.
We used logistic regression models to determine key model parameters that can serve
as patient outcome predictors. In particular we determined biological processes that proved
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to be significant to predict whether a patient will survive or not-survive, including the sce-
nario when nitric oxide inhibition treatment is administered. Similarly, we found significant
parameters to determine outcome within the non-survivor group between aseptic and septic.
As a matter of fact, when classifying survivors and non-survivors, we found 12 parameters
that were significantly good predictors. These include the energy rate µA, the proportion of
energy consumed during phagocytosis c2, the phagocytosis rate kpn, αx which is the scaling
parameter between molecules of nitric oxide and the level of pathogens, and xdn, which is the
half saturation level of the tissue damage marker. For instance, we found that spending too
much energy during phagocytosis, that is high c2 values, has a negative effect for survival,
whereas patients with higher energy rate µA, are more likely to survive.
Similarly, we found that 5 parameters were particularly relevant to predict outcome be-
tween septic or aseptic patients. These parameters are the pathogen growth rate kpg, the
energy µA, the half-activation for the non-specific local response µm, the rate of pathogen
elimination by non-specific local response kpm, and the energy consumption rate of phago-
cytosis c2. The fact that kpg is an important predictor between septic and aseptic does not
come as a surprise, as its relevance was also explored in Chapter 2 and published in [59].
However, the fact that energetics play an important role in this case is part of the new
information we learned with our model.
Lastly, to predict therapy success, we found that pathogen virulence kpg, energy rate
µA, tissue damage half saturation level xdn, and intrinsic decay rate of nitric oxide, µno, are
some of the parameters that play important roles. In particular, patients with high energy
rate are more likely to survive when treatment is administered. Likewise for those whose
pathogen growth rate is low.
We also explore the role of high and low values of inflammatory mediators as well as
low and high glucose in a virtual population. This was accomplished by tuning parameters
involved in anti-inflammatory cytokines production and glucose intake. Our model suggests
that low glucose intake can compromise energy availability to fuel the immune response
leading to an increment in mortality. On the other hand, we found that an increment in
circulating anti-inflammatory cytokines reduces mortality.
Logistic regression models have been used to predict patient outcome in different settings.
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In particular, Seymour et. al [65] used logistic regression to predict outcome in septic patients
using information including systolic blood pressure and patient respiratory rate. However,
caution must be practiced when interpreting the results provided as logistic regression also
has certain limitations. In particular, the analysis assumes the effect of one predictor is not
influenced by the effect of the other. However this is not always true, as there might be
cases when two processes interact with each other but yet be represented by two different
predictors [78].
In a study similar to what we presented in this thesis, Malkin et. al [51] developed a
computational model to explore how different levels of neutrophil activation impact survival
on septic subjects. In particular, they explored the role of different neutrophil phenotypes,
including killer, migratory, and dual neutrophil phenotypes to predict survival in an animal
study. Further, they used an in silico extracorporeal treatment that modulates CXCR-1/2
neutrophil surface receptors and found an improvement in survival when deployed under
certain ranges of conditions. They used parallel tempering for parameter estimation and
stepwise logistic regression to identify model parameters to predict mortality. The animal
data they used was taken from a similar baboon study done by the same group that performed
the baboon study used in this thesis [62]. In this animal study, they followed the same
protocol on which sixteen baboons (Papio ursinus) were infused 2 × 109 CFU intravenous
E.coli for a period of two hours. The study was followed for a maximum of 28 days [63].
In summary in their work, Malkin et. al presented a model that describes interactions of
neutrophils taking into account systemic variables and neutrophil receptors. Our work on
the other hand, not only takes into account the interplay between neutrophils and their
inflammatory effects, but it also takes into account the energy supply and demand required
by netrophils to fight a pathogenic infection and supports previous findings that relate low
ATP levels with sepsis. Also, the fact that we incorporate the link between inflammation
and tissue damage through nitric oxide, allowed us to explore the effect of an alternative
type of therapy (an NOS inhibitor), which was effective in the animal study but has shown
negative results when used in human patients.
Although our model is complex, it is still an oversimplification of the many biological
processes involved during the inflammatory response. Therefore caution should also be
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practiced when interpreting the results presented in this chapter. These results should be
used to complement medical knowledge and other findings in the field.
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6.0 Conclusions
The inflammatory response requires energy. As a result, a diminished energy supply compro-
mises the body’s ability to mount a response to the presence of pathogens or related insults.
Interestingly, since a healthy inflammatory response requires an appropriate balance and
temporal interplay of pro- and anti-inflammatory elements, the effects of this compromise are
not obvious. With reduced energy, the activation and effectiveness of pro-inflammatory com-
ponents are limited, suggesting that the inflammatory response could become inadequate to
eliminate pathogens. Less energy could also prove detrimental by limiting anti-inflammatory
production and allowing inflammation to spiral out of control, or it could prove helpful by
reducing damage-related effects of pro-inflammation. Clearly, the net result of reduced en-
ergy is difficult to predict. A computational model provides a helpful tool for evaluating the
outcome of such tradeoffs in a variety of scenarios.
The goal of the work presented in this thesis was to provide qualitative and quantitative
evidence of the relation between low energy levels combined with high presence of both nitric
oxide and lactate, and the consequential high mortality of sepsis observed in the ICU. More
specifically, we wanted to identify which biological factors play important in distinguishing
between patients that recover from sepsis and those who do not and therefore die.
In general the work presented in this thesis can be divided into two parts; one consisting
of a forward problem and the second of an inverse problem. In the forward problem, we pro-
posed mathematical models that enclose the dynamics of the biological problem of interest.
In the inverse problem, we use parameter estimation techniques to calibrate our model and
extract relevant biological information that can be used to provide feedback and help physi-
cians to make decisions when dealing with septic patients. Moreover, with the parameter
estimates and uncertainty quantification, we explored different scenarios including patient
heterogeneity, and treatment protocols.
More specifically, Chapter 2 consisted in the understanding, development, and imple-
mentation of a mathematical model that connects the acute inflammatory response with
the energy consumption required to accomplish such response. We constructed a theoretical
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model of ordinary differential equations in which we included several metabolic processes
involved in the inflammatory response against pathogens along with the energetic require-
ments for such response to take place. Numerical explorations such as bifurcation analysis
and numerical solutions of variations of the model allowed us to study metabolic conditions
and their effect in a virtual population. We used the model to explore metabolic conditions
like hypoglycemia, hyperglycmia, and hypoxia. The results obtained therein provided qual-
itative features that were consistent with the biology and the literature. Still as part of the
forward problem, in Chapter 3, we followed a data-driven approach to extend our initial
model to a model that includes variables that are typically measured in the ICU including
glucose, lactate, LPS, nitrate, and elastase.
Chapter 4 consists of a backward problem on which animal data was used to obtain
model parameter estimates. We did this in two stages, starting with a standard ordinary
least squares (OLS) like approach to obtain an initial local minimum in the parameter
space for the weighted sum of squares distance function. In the second stage, we followed
a Bayesian approach to quantify uncertainty in the model parameters. In this process, we
constructed a virtual population that resembles the variability observed in the animal data
and that can be used to represent real patient heterogeneity. We validated our model and
the virtual population comparing model results with data via a Metropolis algorithm with
informative prior. We obtained results that were, for the most part, consistent with the data.
We concluded that we can use our model to predict patient outcome from new data and that
early measurement recording is important to improve accuracy of mortality predictions.
In Chapter 5, we used our extended model as a tool to explore the role of hypoglycemia
and hyperglycemia in the virtual population and we observed that these two conditions
benefit sepsis and increase mortality. We further extended our model to study the therapeutic
effect of a nitric oxide inhibitor. We showed how our model can be used to predict patient
outcome with new data from subjects who undergo treatment. We also explored different
therapy protocols based on duration and time of induction and we determined that early
diagnose and therefore early therapy can positively impact survival.
Lastly, with the help of logistic regression models, we identified key parameters that can
be used as patient outcome predictors. We focused on three different scenarios: survivors and
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non-survivors, within the non-survivors septic and aseptic, and survivors and non-survivors
for patients that were treated with an NOS inhibitor. In particular, we found that parameters
like energy rate, half tissue damage saturation constant, and energy consumption rate of
phagocytosis proved to be some of the most significant to predict patient outcome between
survivors and non-survivors. In our model, the energy rate, denoted by µA, appears in the
production and depletion of ATP and hence it is involved in all mechanisms that require
energy to take place, that is all the energy consumption fluxes denoted by Φi in the model
and in the natural elimination of both ATPs, Ab and An. The half tissue damage saturation
constant xdn determines the levels of pathogens and nitric oxide needed to bring tissue
damage production to half its maximum and the energy consumption rate of phagocytosis
is given by c2. Our model suggests that a high energy consumption during phagocytosis
combined with a low energy rate constant could be considered a warning sign. The effects
of a low energy rate constant are complicated as µA participates in both production and
depletion of both ATPs. However, a slow energy rate leads to a slow ATP metabolism which
results in a poor energy availability that compromises the immune response. Therefore
patients with higher energy rate constant and low energy demand during phagocytosis are
more likely to survive.
Similarly, we found that pathogen growth rate, energy rate and the energy consumption
rate of phagocytosis were all good predictors between septic and aseptic subjects. Lastly,
we found 19 parameters that are good predictors of survival in patients that undergo NOS
inhibition treatment. Some of these parameters are again the energy rate, half tissue dam-
age saturation constant, pathogen growth rate, and tissue damage production. Given this
knowledge in impactful parameters we suggest that in order to increase chances of survival
after treatment administration, energy rate must be enhanced.
Our model also suggests that the faster ATP is depleted, the faster energy is being used
to fight the infection. However, there needs to be a balance between energy consumption and
production. Energy must be enough to fuel anti-inflammatory cytokines and tissue healing.
But there needs to be certain control in the amount of energy spent in phagocytosis.
Future directions for extending this work include model variations that will account for
adaptive mechanisms that cells have developed to accommodate shortages in energy supply,
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[66]. We also intend to expand our models to consider the dynamics of different organs in the
host and therefore use it to study multiple organ dysfunction syndrome (MODS). Moreover,
optimal control techniques can be applied to determine optimal treatment strategies to fight
infection and simultaneously reduce side effects [25], [75], [72]. How soon should patients
in the ICU be fed has been a topic of discussion [33]. Optimal control techniques and
model simulations can also be applied to determine optimal timing of nutrition. Finally,
inclusion of certain treatments that address hyperglycemia, hypoglycemia or hypoxia might
also be considered in future work. Hopefully, designing these treatment strategies using
a computational model will allow for approaches that are tailored to individual patient
characteristics, allowing for a much more extensive exploration of options, with a more
refined capability to address specific patient needs, than can be achieved in clinical settings.
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Appendix Individual fits with DRAM
In Section 4.3.3 we found individual fits and envelopes for 16 subjects. However therein we
only presented 4 of the 12 envelopes for the non-survivors. For completeness we present
here the individual envelopes obtained with DRAM by fitting the data of the remainder
non-survivors NS66, NS67, NS69, NS76 in Fig. 63 and NS80, NS92, NS97, and NS104 in
Fig. 64.
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(a) (b) (c) (d)
Figure 63: Envelopes of observed trajectories for subjects (a) NS66, (b) NS67, (c) NS69,
and (d) NS76 obtained with DRAM. The solid blue line corresponds to the median of the
sampled trajectories and the shaded gray regions enclose the 5%− 95% confidence intervals.
The black dots correspond to the data and the bars the average of the standard deviation of
the treated non-survivors. 154
(a) (b) (c) (d)
Figure 64: Envelopes of observed trajectories for subjects (a) NS80, (b) NS92, (c) NS97,
and (d) NS104 obtained with DRAM. The solid blue line corresponds to the median of the
sampled trajectories and the shaded gray regions enclose the 5%− 95% confidence intervals.
The black dots correspond to the data and the bars the average of the standard deviation of
the treated non-survivors. 155
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